Cancer immunotherapy to promote hyperacute rejection

JP2023551305A5Active Publication Date: 2024-12-05CORNELL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023532673
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-30
Filing Date
2021-11-30
Publication Date
2024-12-05
Estimated Expiration
2041-11-30

AI Technical Summary

Technical Problem

Current cancer treatments, particularly combination therapies, face challenges in reducing toxic side effects while maintaining or increasing efficacy, especially in cancers with 'cold' microenvironments lacking immune cells, and there is a need for methods that enhance immune response against solid tumors.

Method used

A novel immunotherapeutic approach using tumor-targeted glycosyltransferases to alter tumor phenotypes by adding non-self tissue blood group antigens, converting tumors into HBGA-incompatible allografts or xenografts, thereby initiating hyperacute rejection.

Benefits of technology

This approach effectively transforms tumors into immunogenic targets, eliciting a vigorous immune response and hyperacute rejection, overcoming the limitations of existing therapies by enhancing treatment efficacy with reduced toxicity.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This application relates to a bifunctional therapeutic agent for treating cancer, comprising a targeting moiety that targets a tumor-associated antigen and an enzyme that, when delivered to a tumor by the targeting moiety, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is linked to the targeting moiety. A method for treating cancer, comprising administering the bifunctional therapeutic agent, is also disclosed. TIFF2023551305000035.tif108170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 119,359, filed November 30, 2020. U.S. Provisional Patent Application No. 63 / 119,359 is incorporated by reference herein in its entirety.

[0002] Field The present disclosure relates to cancer immunotherapy to promote hyperacute rejection. [Background technology]

[0003] background Combination therapy is a commonly accepted and common treatment approach for virtually all types of cancer and has been the standard treatment approach for decades. The basis for the adoption of combination therapy was early experience with chemotherapy, which demonstrated that the rapid mutation rate of cancers rapidly led to the development of resistant strains of tumor cells when only a single drug was used. The goal of combination therapy is to increase efficacy and minimize the development of tumor resistance or escape. This is generally achieved by using two or more anticancer drugs, each with a different mechanism of action, thereby making it more difficult and less likely that resistant tumor cells will develop. The additive or synergistic effects of combining two or more drugs can make the difference between successful and unsuccessful treatment of a patient.

[0004] Many combination treatment regimens are well known in the oncology field. As an example, MOPP (an acronym for mechlorethamine, vincristine, procarbazine, and prednisone) is a curative treatment regimen for Hodgkin's disease. Several different combination regimens (all containing cisplatin, vinblastine, and bleomycin) are accepted for the treatment of testicular cancer, and testicular cancer is curable in up to 98% of diagnosed cases. In total, over 300 different combination regimens have been used.

[0005] A major drawback of combination therapies is that they often also result in increased toxicity. For example, most forms of non-surgical cancer therapy, such as external beam radiation and chemotherapy, have limited efficacy due to toxic side effects on normal tissues and cells and the limited specificity of these treatment modalities for cancer cells. This limitation is even more significant when anti-cancer antibodies are used to target toxic agents, such as isotopes, drugs, and toxins, to cancer sites. This is because anti-cancer antibodies, as systemic agents, also circulate in sensitive cellular compartments, such as the bone marrow. In acute radiation injury, destruction of the lymphoid and hematopoietic compartments is a major cause of sepsis and subsequent death. Therefore, there is a great need for methods to reduce the toxic effects of cancer therapies while maintaining or even increasing efficacy.

[0006] As another option for combination therapy, recent advances in immunotherapy have clearly established that the immune system can be involved in responses to cancer, and these responses can be highly effective and long-lasting. Considerable experience with immune checkpoint blockade suggests that its greatest benefit lies in its application to cancers with relatively high mutational burdens. However, even in these cases, only a minority of patients respond. Some cancers, such as prostate cancer, lack immune cells in the tumor microenvironment. This absence, sometimes referred to as a "cold" microenvironment or immune "desert," severely limits the immune system's ability to activate. Chimeric antigen receptor T (CAR-T) cells and bispecific T cell engagers (BiTEs) utilize antibody targeting of tumor-associated antigens to induce the lytic machinery of T cells to lyse cancer cells. However, to date, the antitumor activity of CAR-T and BiTEs has been limited to hematopoietic cancers rather than common solid tumors. Clearly, additional approaches to treat a variety of cancers are still needed.

[0007] The present disclosure is directed to overcoming these and other deficiencies in the art. Summary of the Invention

[0008] overview One aspect of the present disclosure relates to a bifunctional therapeutic for treating cancer that includes a targeting moiety that targets a tumor-associated antigen and an enzyme that, when delivered to a tumor by the targeting moiety, enzymatically converts the tumor phenotype to that of an incompatible allograft or xenograft, where the enzyme is linked to the targeting moiety.

[0009] Another aspect of the present disclosure relates to a method of treating cancer, comprising the steps of selecting a subject having cancer, providing a bifunctional therapeutic according to the present disclosure, and administering the bifunctional therapeutic to the selected subject under conditions effective to treat the cancer.

[0010] Another aspect of the present disclosure relates to a bifunctional therapeutic for treating cancer, comprising a targeting moiety that targets the prostate-specific membrane antigen (PSMA) / folate hydrolase 1 (FOLH1) receptor and a glycosyltransferase that, when delivered to a tumor by the targeting moiety, enzymatically converts the tumor phenotype to that of an incompatible allograft or xenograft, wherein the glycosyltransferase is attached to the targeting moiety.

[0011] Another aspect of the present disclosure relates to a bifunctional therapeutic for treating cancer comprising a targeting moiety that targets a human epidermal growth factor receptor (HER) family member and a glycosyltransferase that, when delivered to a tumor by the targeting moiety, enzymatically converts a tumor phenotype to that of an incompatible allograft or xenograft, wherein the glycosyltransferase is attached to the targeting moiety.

[0012] Another aspect of the present disclosure relates to a bifunctional therapeutic for treating cancer comprising a targeting moiety that targets CD19 and a glycosyltransferase that, when delivered to a tumor by the targeting moiety, enzymatically converts a tumor phenotype to that of an incompatible allograft or xenograft, wherein the glycosyltransferase is attached to the targeting moiety.

[0013] A novel immunotherapeutic approach is presented in which tumor-targeted glycosyltransferases alter the glycophenotype of tumors and / or their vasculature by adding non-self blood group antigens (HBGAs) or α-gal glycotopes. This effectively converts tumors to HBGA-incompatible allografts or xenografts. An exemplary embodiment of this multifunctional agent can target PSMA / FOLH1 to convert tumor neovasculature to incompatible HBGAs or xenografts, thereby initiating hyperacute rejection. Half a century of transplant experience has documented that HBGA-incompatible allografts or α-gal-expressing xenografts stimulate a vigorous immune rejection process.

[0014] As described herein, to induce the expression of heterologous or allologous antigens by tumors, heterologous or allologous glycosyltransferases, such as α-gal transferase (α-galT) or allologous glycosyltransferase A and / or B enzymes, all of which are normally located in the Golgi, are delivered to the tumor cell surface, effectively creating a molecular-scale ectopic allograft / xenograft. Alternatively, α-galT, A, and / or B enzymes can be targeted to antigens specific to tumor neovascular endothelial targets, such as folate hydrolase 1 (FOLH1) (also known as prostate-specific membrane antigen (PSMA)) or vascular endothelial growth factor receptor-2 (VEGFR-2), or other targets known to those skilled in the art. In addition to targeting glycosyltransferases (α-galT, glycosyltransferase A, and / or B enzymes), the respective sugar-nucleotide donors (UDP-gal or UDP-NAcGal) are provided. The presence of glycosyltransferases in tumors can add sugars (Gal or NAcGal) to existing glycoproteins and glycolipids, including products secreted by target cells, to generate alloantigens or xenoantigens, thereby eliciting a strong immune response. The converted alloantigens / xenoantigens secreted into the microenvironment bind to abundant natural antibodies, which induce complement activation, immune responses, and antibody-dependent cellular cytotoxicity (ADCC), helping to convert a "cold" microenvironment into a "hot" one.

[0015] Glycosyltransferase A and glycosyltransferase B enzymes differ in only four of 353 amino acid residues (Hakomori, "Antigen Structure and Genetic Basis of Histo-Blood Groups A, B and O: Their Changes Associated With Human Cancer," Biochimica et Biophysica Acta 1473:247-266 (1999); Seto et al., "Sequential Interchange of Four Amino Acids From Blood Group B to Blood Group A Glycosyltransferase Boosts Catalytic Activity and Progressively Modifies Substrate Recognition in Human Recombinant Enzymes," J. Biol. Chem. 272:14133-14138 (2009), which are incorporated by reference in their entireties. (1997), and therefore unlikely to be immunogenic. Studies of patient sera have confirmed that these enzymes are not immunogenic as expected. Indeed, although these HBGA carbohydrate products are highly immunogenic, transferase A and transferase B enzymes have never been reported to be immunogenic. Tumor-targeted delivery of non-immunogenic transferase A or B enzymes provides a means to alter the immunophenotype of tumors or neovasculature to one that expresses highly immunogenic non-self HBGAs, thereby presenting the phenotype of an incompatible allograft and promoting a vigorous rejection response by the host.

[0016] As described herein, for proof-of-concept purposes, the approach was validated using human-derived GTA or GTB. Alternatively, a heterologous α-gal transferase (α1,3 galactosyltransferase; α-galT) enzyme, which is mutated / non-functional in humans and is responsible for causing rejection of xenotransplanted organs derived from other mammals, could be utilized. Use of the α-galT enzyme may require humanization or deimmunization of α-galT, and there are methods known in the art for accomplishing this, including, but not limited to, the use of homologous region sequences from other glycosyltransferases that are not immunogenic in humans. Such humanization or deimmunization methods have been widely and successfully used to humanize or deimmunize foreign antibodies prior to use as therapeutic agents in humans. However, studies of patient sera have shown that these enzymes are not immunogenic.

[0017] This disclosure presents a novel immunotherapeutic approach in which tumor-targeted glycosyltransferases alter the expression of histo-blood group antigens in tumors and / or their blood supply. This effectively converts tumors to HBGA-incompatible allografts. This multifunctional agent can be used to target PSMA / FOLH1 to convert tumor neovasculature to incompatible HBGAs, thereby initiating hyperacute rejection.

[0018] As described herein, a complementary orthogonal immunotherapeutic approach has been developed based on the active immune response to xenografts or allografts and the understanding of the rejection process that has evolved over the past half century. To accomplish this, the most extreme form of the host-body graft response, namely hyperacute rejection (HAR), was chosen as a model.

[0019] HAR occurs as a result of ancestral mutations in either of two highly related genes: α1,3 galactosyltransferase (α1,3GalT) in the case of xenografts (Collins, et al., "Cardiac Xenografts Between Primate Species Provide Evidence for the Importance of the Alpha-Galactosyl Determinant in Hyperacute Rejection," J. Immunol. 154:5500-5510 (1995)), which is incorporated by reference in its entirety), and the well-known histo-blood group antigen (HBGA) locus in the case of allografts (Milland et al., "ABO Blood Group and Related Antigens, Natural Antibodies and Transplantation," Tissue Antigens 68:459-466 (2006)), which is incorporated by reference in its entirety. These two highly related genes are found on the same chromosome (9q34), share 45% homology, and are believed to have originated from the same ancestral gene (Yamamoto et al., "Molecular Genetic Basis of the Histo-Blood Group ABO System," Nature 345:229-233 (1990); Yamamoto et al., "Sugar-Nucleotide Donor Specificity of Histo-Blood Group A and B Transferases is Based on Amino Acid Substitutions," J. Biol. Chem. 265:19257-19262 (1990); Yamamoto et al., "Genomic Organization of Human Histo-Blood Group ABO Genes," Glycobiology 5:51-58 (1995), all of which are incorporated by reference herein in their entireties).These alleles encode glycosyltransferases that post-translationally add terminal sugar moieties to carbohydrate (CHO) chains present in nascent proteins and lipids destined for cell membrane expression or secretion. The αGalT enzyme in humans and Old World monkeys was inactivated approximately 28 million years ago due to mutation, but has not been inactivated in other mammals (Macher et al., "The Gal Alpha1,3Gal Beta1,4GlcNAc-R (Alpha-Gal) Epitope: a Carbohydrate of Unique Evolution and Clinical Relevance," Biochim. Biophys. 1780:75-88 (2008)), incorporated herein by reference in its entirety). As a result, xenotransplanted organs and tissues derived from non-primate mammals express the α-gal epitope, which is foreign to humans. In the case of the HBGA locus, a small number of mutations have given rise to the alleles classically known as A, B, and O. The B allele encodes glycosyltransferase B (GTB), which, like its α1,3GalT homolog, adds a terminal Gal to the CHO chain. The only difference is that transferase B adds Gal only if 1,2-fucose is present on the adjacent Gal. Transferase A is functionally distinct from transferase B only in that it adds an N-acetylated terminal Gal (NAcGal). The O gene product is inactive due to a frameshift mutation (Figure 1).

[0020] The α-Gal, HBGA A, and HBGA B epitopes generated by these three active enzymes are widely expressed in nature, including in bacteria inhabiting the human gastrointestinal tract (Springer et al., "Blood Group Isoantibody Stimulation in Man by Feeding Blood Group-Active Bacteria," J. Clin. Invest. 48:1280-1291 (1969), incorporated herein by reference in its entirety.) As a result, humans lacking aGalT and the A and / or B alleles are constantly immunized with these bacterial-derived epitopes. This results in very high levels of natural antibodies (Abs) against these non-self epitopes, constituting over 1% of plasma immunoglobulins (Igs) (Galili et al., "One Percent of Human Circulating B Lymphocytes Are Capable of Producing the Natural Anti-Gal Antibody," Blood 82:2485-2493 (1993); Galili et al., "A Unique Natural Human IgG Antibody With Anti-Alpha-Galactosyl Specificity," J. Exp. Med. 160:1519-1531 (1984), which are incorporated by reference in their entireties.) Given the diversity of the Ab repertoire, estimated at billions of different specificities, this represents a very large proportion of endogenous Ig activity.These Abs are composed of IgM and IgG, which can activate the complement cascade and subsequently initiate vascular thrombosis (Subramaniam et al., "Distinct Contributions of Complement Factors to Platelet Activation and Fibrin Formation in Venous Thrombus Development," Blood 129(16):2291-2302 (2017); Foley et al., "Cross Talk Pathways Between Coagulation and Inflammation," Circ. Res. 118:1392-1408 (2016); and Conway EM, "Reincarnation of Ancient Links Between Coagulation and Complement," J. Thromb. Haemost. 13(Suppl. 1):S121-S32 (2015), which are incorporated by reference in their entireties). Other immunoglobulin classes, such as IgA and IgE, can also be directed against these glycol-epitopes. Indeed, evolutionary mutations in these two genes create an immunological state that is kept at a tipping point, primed, and ready to respond rapidly, aggressively, and destructively to the appearance of any of these non-self epitopes. The immunological effects of these mutations have hindered the success of xenografts in humans, explaining why HBGA matching has been the single most important match in solid organ transplantation since its critical importance was first recognized in the early days of kidney allotransplantation in the 1960s by Starzl, Experience In Renal Transplantation. (WB Saunders Company, Philadelphia, PA, chapter 6 (1964)), which is incorporated herein by reference in its entirety.Since then, the devastating effects of HBGA mismatch in solid organ transplantation have been observed only in very rare cases where iatrogenic errors have occurred (Altman, Doctors Discuss Transplant Mistake. New York Times, Feb. 22, 2003, which is incorporated by reference herein in its entirety.) Against this background, the goal has been to induce the expression of one of these non-self epitopes by the host's cancer cells and / or by the vascular endothelial cells that supply the tumor. [Brief explanation of the drawings]

[0021] [Figure 1] Figure 1 illustrates the strict acceptor substrate specificity of glycosyltransferases. The B (or A)-transferase simply adds its respective sugar to glycosylation sites expressing the H antigen. Fortunately, many normal tissues lack the necessary H antigen, preventing off-target conversion to HBGA A or B. Alternatively, if it is desired to intentionally target normal or cancer cell types that naturally lack the H antigen, this can be accomplished by also targeting α1-2 fucosyltransferase and providing GDP-fucose as the fucose donor, in a manner similar to that described for the addition of A or B. The addition of fucose / H antigen can be performed simultaneously with the targeted A or B transferase, or this addition can be performed stepwise (e.g., adding fucose first, followed by A or B). [Figure 2]Figures 2A-2B show that the chimeric Ab-GTB protein maintains immunoreactivity and enzymatic activity. Figure 2A is a graph showing that the J591-GTB chimeric protein maintains comparable PSMA binding immunoreactivity compared to the parent J591 antibody, as measured by ELISA. Figure 2B is a bar graph showing that the chimeric protein also retains enzymatic activity, as evidenced by its ability to catalyze 14C-galactose transfer from the nucleotide donor UDP-14C-galactose to 2'-fucosyl-lactose (2-FL). This incorporation occurs at high levels only in the presence of the J591-GTB fusion protein and its acceptor substrate, 2-FL. Similar results were obtained using anti-4D5(her2)-GTB. [Figure 3] Figure 3 is a graph showing that GTB activity can be modulated by C-terminal extension. J591-GTB activity (% of control) is shown as a function of increasing length of the C-terminal amino acid extension, as measured by incorporation of 14C-gal from UDP-14C-gal into 2'-fucosyl-lactose (2-FL). [Figure 4] Figure 4 shows that J591-GTB specifically converts antigen-positive tumor cells. Tissue sections from CWR22Rv1 xenografts (heterologously PSMA+ / HBGA O) were incubated with J591-GTB and UDP-gal and then immunohistochemically stained for HBGA B expression (left panel). Negative control sections containing secondary anti-mouse Ig-peroxidase but no mouse anti-HBGA B (middle panel) or J591-GTB (right panel) were unstained. [Figure 5] Figure 5 shows the effects of J591-GTB on LNCaP and PC3 cells. LNCaP cells (PSMA+ / HBGA O; left panel) were converted to HBGA B by J591-GTB. PC3 cells (PSMA- / HBGA O; right panel) were not converted by J591-GTB. [Figure 6]Figures 6A-6D are images showing PC3 cells transfected with PSMA and then treated with J591-GTB. Figure 6A shows a phase-contrast image. Figure 6B shows PSMA-expressing cells. Figure 6C shows HBGA B antigen expression. Figure 6D is a composite of Figures 6B and 6C. Only PSMA-expressing cells were converted to HBGA B expression. PSMA-negative cells, primarily located in the left center and upper center, remained HBGA B-negative. [Figure 7] Figure 7 shows images of LNCaP cells incubated with J591 (top row); J591-GTB (middle row), or J591-GTB-54aa extension (bottom row) in addition to a type O RBC suspension. The left column shows phase-contrast images. The middle column shows DAPI nuclear staining. The right column shows mouse anti-HBGA B+ goat anti-mouse IgM-alexa488. PSMA-pos LNCaP cells, but not PSMA-neg RBCs, were converted to HBGA B-pos by J591-GTB bound to the cell plasma membrane, with or without the C-terminal extension. [Figure 8] Figures 8A-8D are images showing complement-mediated lysis in vitro. LNCaP cells were incubated with either native mAb J591 or mAb J591-GTB fusion protein. All wells also contained UDP-gal. Serum from a type A patient was then added as a source of native anti-B Ab and complement. The combination of J591-GTB and type A serum (Figure 8A) completely lysed LNCaP. The J591-GTB fusion protein did not induce lysis in the absence of type A serum (Figure 8B). Without the fusion protein, no lysis was detected, regardless of the presence (Figure 8C) or absence (Figure 8D) of type A serum. [Figure 9]Figure 9 shows images demonstrating complement-mediated cytotoxicity of several cell lines, as observed by trypan blue exclusion. The upper panel shows cells treated with J591-GTB + UDP-gal + human type O serum. In the lower panel, cells were treated with the same type O serum but without J591-GTB + UDP-gal. The percentage of dead cells determined by FACS is reported below each photograph (Figure 10). For FACS, J591-GTB + type O serum without UDP-gal served as a negative control. In contrast, 0.1% triton exposure served as a complete lysis control. [Figure 10-1] Figures 10A-10H are images demonstrating in vivo conversion of prostate and breast cancer cells to HBGA B. Figures 10A-10D show serial sections from LNCaP xenografts in SCID mice 24 hours after administration of a) PBS + UDP-gal (Figure 10A), b) J591 + UDP-gal (Figure 10B), and c) J591-GTB + UDP-gal (Figure 10C). Figures 10A-10C are immunohistochemically stained for HBGA B (all 10x magnification). Figure 10D shows serial sections from the same specimen stained for PSMA. See also Figures 12A-12E for higher magnification and additional xenograft lines. Figures 10E-10H show MD-MB361 breast cancer (HER2+) xenografts after treatment with PBS + UDP-gal (Figure 10E), 4D5 + UDP-gal (Figure 10F), and 4D5-GTB + UDP-gal (Figures 10G and 10H). Sections were immunohistochemically stained for HBGA B expression. Distinct plasma membrane staining is evident. In Figures 10C and 10H, adjacent connective tissue is untransformed, demonstrating that the specificity of immunophenotype conversion is restricted to the target tumor. [Figure 10-2] See description of Figure 10-1. [Figure 11A]Figures 11A-11B are bar graphs (Figure 11A) and histograms (Figure 11B) showing lysis of B-converted cell lines by type O serum, as determined by propidium iodide uptake and trypan blue exclusion (see Figure 9) measured by FACS. In the absence of B conversion, type O serum does not cause lysis. After treating PSMA-pos cells with J591-GTB + UDP-gal, type O serum completely lysed all of the PSMA-pos / B-converted cell lines. PC3 is an HBGA O-pos / PSMA-neg, did not convert to HBGA B, and was not lysed. [Figure 11B-1] See legend to Figure 11A. [Figure 11B-2] See legend to Figure 11A. [Figure 11B-3] See legend to Figure 11A. [Figure 12] Figures 12A-12E are images showing in vivo conversion of LNCaP, C4-2, and CWR22Rv1 xenografts by J591-GTB. Figures 12A-12B show LNCaP xenografts treated in vivo with J591 [without GTB] (Figure 12A) or J591-GTB (Figure 12B), both with UDP-gal, and immunohistochemically stained with mouse anti-HBGA B. High magnification. Figure 12C shows C4-2 prostate cancer treated in vivo with J591-GTB + UDP-gal and immunohistochemically stained with mouse anti-HBGA B. High magnification. Figures 12D-12E show CWR22Rv1 prostate cancer treated in vivo with J591-GTB + UDP-gal, which is heterogeneous and weakly PSMA-positive. Adjacent connective tissue was not converted to HBGA B. [Figure 13A]Figures 13A-13B show graphs (Figure 13A) and in vivo images (Figure 13B) of mice demonstrating in vivo transformation and treatment with HBGA. Mice were IP-implanted with 10 x 10 C4-2-luc cells suspended in Matrigel. Bioluminescence was measured several days later, and 10 mice with confirmed, viable tumors were randomly assigned to one of two treatment groups. All tumor-bearing mice received a single dose of J591-GTB + UDP-gal + human type O serum. In half of the mice, serum was heat-inactivated before injection. In mice treated with activated type O serum, the mean photon flux progressively decreased over the next 13 days, while mice treated with inactivated serum experienced average tumor progression. The difference in bioluminescence between groups was significant (p<0.0032) at the end of the experiment on day 13. Consistent results were obtained from two repeated experiments. [Figure 13B-1] See legend to Figure 13A. [Figure 13B-2] See legend to Figure 13A. [Figure 14A-1] Figures 14A-14B are in vivo images and graphs showing the results of Experiment #2, in which C4-2-luc cells were IP implanted followed by a single treatment with J591-GTB + UDP-gal + human O serum (top row) (Figure 14A). Figure 14A shows images of mice given active O serum or O serum that had previously been heat-inactivated. Mice given heat-inactivated serum demonstrated tumor progression (see photon flux plot; Figure 14B), while mice given active serum experienced tumor regression. The results of Experiment 1 are shown in Figures 13A-13B. [Figure 14A-2] See legend to Figure 14A-1. [Figure 14B] See legend to Figure 14A-1. [Figure 15] Figure 15 is a FACS histogram showing CD19, CD20, and CD38 expression in MM1-S cells. Flow cytometry analysis showed that the MM1-S multiple myeloma cell line was CD38-positive, CD19-positive, and CD20-negative. [Figure 16A]Figures 16A-16B are FACS histograms showing ABO expression in MM1-S cells. Figure 16A shows that the MM1-S multiple myeloma cell line is A / B negative. Figure 16B shows that the MM1-S multiple myeloma cell line is O positive. [Figure 16B] See legend to Figure 16A. [Figure 17] Figure 17 is a FACS histogram showing that CD19+ / O+ MM1-S myeloma cells can be converted to B+ by GTB+UDP-gal. GTB can be targeted to myeloma cells using anti-CD19, anti-CD38, or anti-BCMA. [Figure 18] Figure 18 shows images demonstrating that the use of ACUPA, a PSMA-binding small molecule ligand conjugated to GTB (ACUPA-GTB), induces LNCaP conversion of HBGA O to HBGA B. This demonstrates that in addition to antibodies (or antibody derivatives), small molecule ligands or peptides that bind to target antigens on the surface of tumor cells or neovascular endothelium can also be used for enzyme targeting. The left panel shows cells treated with ACUPA-PEG-1500-GTB. The right panel shows cells treated with GTB alone. [Figure 19] Figure 19 shows images demonstrating the specificity of HBGA O to HBGA B conversion. SK-BR5 breast cancer cells (PSMA- / O+) were cocultured with LNCaP prostate cancer cells (PSMA+ / O+). The two cell types can be distinguished by morphology: SK-BR5 cells are round, whereas LNCaP cells are oval / spindle-shaped. Furthermore, LNCaP cells were labeled with green fluorescent protein (GFP). Incubation with J591-GTB and UDP-gal converts only PSMA+ LNCaP cells, while neighboring cells lacking PSMA targets remain. The panels show DAPI (left panel), GFP (middle panel), and anti-B (Cy5) (right panel) imaging. [Figure 20]Figure 20 is an image demonstrating the specificity of the conversion of HBGA O to HBGA B. As shown, only PSMA+ cells are converted to B+ by J591-GTB / UDP-gal. [Figure 21A] Figures 21A-21B are FACS histograms demonstrating the specificity of HBGA O to HBGA B conversion. The specificity of conversion was quantified using FACS by comparing the J591 (anti-PSMA)-GTB concentrations required to convert LNCaP (PSMA+) to HBGA B (Figure 21A) compared with SK-BR5 (PSMA-neg) cells (Figure 21B). Both cell lines are O+. FACS histograms are shown. B conversion in SK-BR5 does not occur even at J591-GTB concentrations up to 100 μg / mL. In contrast, conversion of PSMA-positive LNCaP cells is induced at concentrations as low as 0.012 μg / mL. [Figure 21B] See legend to Figure 21A. [Figure 22] Figure 22 is a table and graph showing the specificity of HBGA O to HBGA B conversion. A table (left panel) and histogram (right panel) of the MFI from Figures 21A-21B are shown. The specificity index is greater than 8,000:1. [Figure 23] 23 is a table and graph showing that both cell surface and secreted glycoproteins are glycosylated by the methods of the present disclosure. A graph (upper panel) and table (lower panel) of cell numbers are shown. [Figure 24] Figures 24A-24B are plots showing the testing of anti-α1,3GalT antibodies in serum samples, and Figure 24B is an enlarged view of Figure 24A showing low optical density. [Figure 25] FIG. 25 is an SDS-PAGE gel showing the expression and purification of the recombinant protein. [Figure 26] 26A-26B are graphs showing binding of scfv-CD19-αGal to CD19-MM1.S cells (FIG. 26A) and CD19+ Raji cells (FIG. 26B). [Figure 27]FIG. 27 is a graph showing galactose transfer assays for CD19+ and CD19− cells. [Figure 28] FIG. 28 is a histogram showing a galactose transfer assay on CD19+ cells. [Figure 29] FIG. 29 is a scatter plot showing binding of scfv-αGT to human B cells and αGal transfer assays. [Figure 30] FIG. 30 is a dot plot showing a serum-mediated lysis assay for CD19+ cells. [Figure 31] Figures 31A-31B are graphs showing lysis assays of αGal-transfected B cells. Figure 31A is a graph showing % lysis. Figure 31B is a graph showing IgG levels (MFI) and IgM levels. [Figure 32A] Figures 32A-32C show in vitro checkerboard assays of scfv-CD19-αGT with UDP-Gal: Figure 32A measures binding, Figure 32B measures α-gal expression, and Figure 32C measures lysis by human PBMCs. [Figure 32B] See legend to Figure 32A. [Figure 32C] See legend to Figure 32A. [Figure 33] Figure 33 is a bar graph showing the percent remaining B cells at baseline and 1 hour, 4 hours, 1 day, 7 days, 14 days, 30 days, and 60 days after administration of anti-CD19 scFv-αGal transferase fusion protein and UDP-gal. B cell counts were determined by examining CD20+ / CD3- fluorescence. CD20 was used to avoid misinterpretation of B cell counts due to the presence of anti-CD19 scFv. DETAILED DESCRIPTION OF THE INVENTION

[0022] Detailed Description The present disclosure discloses a bifunctional therapeutic for treating cancer, comprising a targeting moiety that targets a tumor-associated antigen and an enzyme that, when delivered to a tumor by the targeting moiety, enzymatically converts the tumor phenotype to that of an incompatible allograft or xenograft, wherein the enzyme is linked to the targeting moiety.

[0023] The targeting moiety may be antibody-derived (intact, monovalent single chain, Fab'2, Fab, scFv, etc.) or may be a peptide. The targeting moiety and the enzymatic moiety may be linked by creating a fusion gene / protein or via biochemical conjugation.

[0024] The present disclosure also relates to a method of treating cancer, comprising selecting a subject with cancer and providing a bifunctional therapeutic according to the present disclosure, wherein the bifunctional therapeutic is administered to the selected subject under conditions effective to treat the cancer.

[0025] The term "treating" as used herein refers to the application or administration of a bifunctional therapeutic of the present disclosure to a subject, e.g., a patient. Treating may be curing, curing, alleviating, mitigating, altering, palliating, ameliorating, ameliorating, improving, or affecting cancer, the symptoms of cancer, or the predisposition to cancer.

[0026] As used herein, the term "subject" is intended to include human and non-human animals. Non-human animals include all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dogs, cows, chickens, amphibians, reptiles, etc.

[0027] As used herein, the term "cancer" includes all types of cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, regardless of histopathological type or stage of invasiveness.

[0028] As used herein, "incompatible allograft" refers to a tissue or tumor that induces hyperacute, acute, and / or chronic immune rejection. Hyperacute rejection occurs minutes to hours after organ transplantation, i.e., after the bifunctional therapeutic agent is delivered and the tumor or tissue is transformed as described herein. This rapid rejection is characterized by vascular thrombosis, which leads to necrosis of the graft / tumor. Hyperacute rejection is caused by the presence of anti-donor antibodies in the recipient prior to transplantation / transformation.

[0029] As used herein, a "targeting moiety" refers to a moiety that can bind to or otherwise associate with a tumor-associated antigen. Such tumor-associated antigens include the following tumor-associated antigens and peptide fragments thereof: FOLH1 / PSMA, VEGFR, CD19, CD20, CD25, CD30, CD33, CD38, CD52, B-cell maturation antigen (BCMA), CD79, somatostatin receptor, 5T4, gp100, carcinoembryonic antigen (CEA), mammoglobin A, melan-A / MART-1, MAGE, NY-ESO-1, PSA, tyrosinase, HER-2 / neu, HER-3, EGFR, hTERT, mesothelin, nectin-4, TROP-2, tissue factor, MUC-1, CA-125, and peptide fragments thereof, proteins. Examples of tumor-associated antigens include, but are not limited to, tumor-associated antigens such as MZ2-E, polymorphic epithelial mucin, folate-binding protein, cancer-testis protein MAGE-1 or MAGE-3 or NY-ESO-1, human chorionic gonadotropin (HCG), alpha-fetoprotein (AFP), pancreatic carcinoembryonic antigen (CA-15-3, 19-9, 549, 195), squamous cell carcinoma antigen (SCCA), ovarian cancer antigen (OCA), pancreatic cancer-associated antigen (PaA), mutant K-ras protein, mutant p53, non-mutated p53, truncated epidermal growth factor receptor (EGFR), chimeric protein p210BCR-ABL, telomerase, survivin, WT1 protein, LMP2 protein, HPV E6E7 protein, idiotype protein, and PAP protein. The foregoing list exemplifies tumor-associated antigens. Additional tumor-associated antigens are known to those skilled in the art.

[0030] The antigen may be, for example, an antigen or epitope present on a tumor cell in the lung, breast, esophagus, intestine, stomach, rectum, kidney-urinary system, prostate, bladder, brain, thyroid, liver, pancreas, spleen, skin, connective tissue, heart, blood system, or vasculature. The target antigen may be an antigen or epitope present on a cell membrane, on the surface of a secreted protein, or on the surface of a non-membrane-bound protein. Examples of secreted proteins include, but are not limited to, hormones, enzymes, toxins, and antimicrobial peptides.

[0031] The targeting moiety may be localized or concentrated at a particular targeting site, such as a tumor, disease site, tissue, organ, cell type, infectious bacteria or virus, and the like.

[0032] For example, contemplated targeting moieties include peptides, polypeptides, proteins, glycoproteins, aptamers, carbohydrates, or lipids. Targeting moieties can be natural or synthetic ligands for cell surface receptors, such as growth factors, hormones, LDL, transferrin, and the like. Targeting moieties can also be antibodies, and the term is intended to include antibody fragments and derivatives, distinctive portions of antibodies, e.g., single-chain targeting moieties that can be identified using procedures such as phage display. Targeting moieties can also be natural or artificially created (e.g., via chemical synthesis), targeting peptides, targeting peptidomimetics, or small molecules.

[0033] In one embodiment, the targeting moiety is selected from the group consisting of an antibody or antigen-binding fragment thereof, a protein, a peptide, and an aptamer, and a small molecule.

[0034] Antibodies against tumor-associated antigens are known.For example, antibodies and antibody fragments that specifically bind to markers produced by or associated with tumors are disclosed in, among others, U.S. Patent No. 3,927,193 to Hansen, and U.S. Patent Nos. 4,331,647, 4,348,376, 4,361,544, 4,468,457, 4,444,744, 4,818,709, and 4,624,846 to Goldenberg, which are incorporated herein by reference in their entirety.In particular, antibodies against tumor-associated antigens, such as gastrointestinal tumors, lung tumors, breast tumors, prostate tumors, ovarian tumors, testicular tumors, brain tumors, or lymphatic or hematopoietic tumors, sarcomas, or melanomas, are advantageously used.Antibodies against tumor-associated antigens are well known to those skilled in the art.

[0035] Antibodies of the present disclosure can exist in a variety of forms, including, for example, polyclonal antibodies, monoclonal antibodies, intracellular antibodies ("intrabodies"), antibody fragments (e.g., Fv, Fab, and F(ab)2), half-antibodies, hybrid derivatives, as well as single-chain antibodies (scFv), chimeric antibodies, and deimmunized or humanized antibodies (Ed Harlow and David Lane, USING ANTIBODIES: A LABORATORY MANUAL (Cold Spring Harbor Laboratory Press, 1999); Houston et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in Escherichia coli", Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); Bird et al., "Single-Chain Antigen-Binding Proteins", Science 242:423-426 (1988), each of which is incorporated by reference herein in its entirety.

[0036] The antibodies of the present disclosure may also be produced using recombinant DNA technology, such as, for example, bacteriophage-expressed antibodies or fragments thereof. Alternatively, synthetic antibodies are produced by synthesizing a DNA molecule that encodes and expresses an antibody of the present disclosure, or by synthesizing an amino acid sequence that specifies the antibody. In this case, the DNA or amino acid sequence is obtained using synthetic DNA or amino acid sequence techniques available and well known in the art.

[0037] Methods for monoclonal antibody production may be performed using techniques described herein or are well known in the art (MONOCLONAL ANTIBODIES - PRODUCTION, ENGINEERING AND CLINICAL APPLICATIONS (Mary A. Ritter and Heather M. Ladyman eds., 1995), which is incorporated by reference in its entirety. Generally, the process involves obtaining immune cells (lymphocytes) from the spleen of a mammal that has been previously immunized with an antigen of interest, either in vivo or in vitro.

[0038] Alternatively, monoclonal antibodies can be made using recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567 to Cabilly et al., incorporated herein by reference in its entirety. Polynucleotides encoding monoclonal antibodies are isolated from mature B cells or hybridoma cells, for example, by RT-PCR using oligonucleotide primers that specifically amplify genes encoding the antibody heavy and light chains. The isolated polynucleotides encoding the heavy and light chains are then cloned into an appropriate expression vector and introduced by transfection into host cells that do not otherwise produce immunoglobulin protein, such as Escherichia coli (E. coli) cells, simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells, resulting in the production of the monoclonal antibody by the host cells. Similarly, recombinant monoclonal antibodies or fragments thereof of the desired species can be isolated from phage display libraries (McCafferty et al., "Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains," Nature 348:552-554 (1990); Clackson et al., "Making Antibody Fragments using Phage Display Libraries," Nature 352:624-628 (1991); and Marks et al., "By-Passing Immunization. Human Antibodies from V-Gene Libraries Displayed on Phage," J. Mol. Biol. 222:581-597 (1991), which are incorporated by reference in their entireties).

[0039] Polynucleotides encoding monoclonal antibodies can be further modified using recombinant DNA technology to generate alternative antibodies or derivatives. For example, the light and heavy chain constant domains of a mouse monoclonal antibody can be replaced with those from a human antibody to generate a chimeric antibody. Alternatively, the light and / or heavy chain constant domains of a monoclonal antibody can be replaced with non-immunoglobulin polypeptides to generate a fusion antibody. In other embodiments, the constant region is truncated or removed to generate the desired antibody fragment of the monoclonal antibody. Furthermore, site-directed mutagenesis or high-density mutagenesis of the variable region can be used to optimize the specificity and affinity of the monoclonal antibody.

[0040] The monoclonal antibody of the present disclosure may be a humanized antibody. A humanized antibody is an antibody that contains minimal sequences derived from non-human (e.g., mouse) antibodies within the variable region. Such antibodies are used therapeutically to reduce antigenicity and human anti-mouse antibody responses when administered to a human subject. In practice, humanized antibodies are typically human antibodies with minimal or no non-human sequences. A human antibody is an antibody produced by a human or has an amino acid sequence corresponding to an antibody produced by a human.

[0041] In addition to whole antibodies, the present disclosure includes antigen-binding portions of such antibodies. Such binding portions include monovalent Fab fragments, Fv fragments (e.g., single-chain antibodies, scFv), as well as single variable V fragments. H and V Ldomains, as well as F(ab')2 fragments, Bis-scFv, diabodies, triabodies, minibodies, etc. These antibody fragments may be produced by conventional procedures, such as proteolytic fragmentation procedures as described in James Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE 98-118 (Academic Press, 1983), and Ed Harlow and David Lane, ANTIBODIES: A LABORATORY MANUAL (Cold Spring Harbor Laboratory, 1988), which are incorporated by reference herein in their entireties, or by other methods known in the art.

[0042] Additionally, particularly in the case of antibody fragments, it may be desirable to modify antibodies to increase their serum half-life. This can be accomplished, for example, by mutating appropriate regions in the antibody fragment, by incorporating a salvage receptor binding epitope into the antibody fragment, or by incorporating the epitope into a peptide tag (e.g., by DNA or peptide synthesis) and then fusing it to the end or center of the antibody fragment.

[0043] Antibody mimetics are also suitable for use in accordance with the present disclosure. 10Fn3) (Koide et al., "The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins", J. Mol. Biol. 284:1141-1151 (1998); Koide et al., "Probing Protein Conformational Changes in Living Cells by Using Designer Binding Proteins: Application to the Estrogen Receptor", Proc. Natl. Acad. Sci. USA 99:1253-1258 (2002), each of which is incorporated by reference in its entirety); and antibody mimics known as affibodies, derived from the stable alpha-helical bacterial receptor domain Z of staphylococcal protein A (Nord et al., "Binding Proteins Selected from Combinatorial Libraries of an alpha-helical Bacterial Receptor Domain", Nature Biotechnol. 2009, 101:1021-1032 (2011), each of which is incorporated by reference in its entirety). Numerous antibody mimetics are known in the art, including, but not limited to, (15(8):772-777 (1997)).

[0044] In certain embodiments, the targeting moiety targets the prostate-specific membrane antigen (PSMA) receptor.

[0045] As used herein, "PSMA" or "prostate-specific membrane antigen" protein refers to mammalian PSMA, preferably human PSMA protein. PSMA is sometimes called folate hydrolase 1 (FOLH1) when encoded by the FOLH1 gene. The long transcript of PSMA encodes a protein product with a molecular weight of approximately 100-120 kDa, which shares sequence homology with the transferrin receptor and is characterized as a type II transmembrane receptor with NAALADase activity (Carter et al., "Prostate-Specific Membrane Antigen is a Hydrolase With Substrate and Pharmacologic Characteristics of a Neuropeptidase," Proc. Natl. Acad. Sci. USA 93:749-753 (1996); Israeli et al., "Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen," Cancer Research 53:227-230 (1993), the entire contents of which are incorporated herein by reference).

[0046] A monoclonal anti-PSMA antibody can be used as the targeting component in the bifunctional therapeutic of the present disclosure. Preferably, the monoclonal antibody binds to the extracellular domain of PSMA (i.e., a PSMA epitope located extracellularly, e.g., a PSMA epitope located at approximately amino acids 44-750 of human PSMA, which amino acid residues correspond to the human PSMA sequence disclosed in U.S. Patent No. 5,538,866, the entire contents of which are incorporated herein by reference). Examples of murine monoclonal antibodies against human PSMA include, but are not limited to, E99 produced by the hybridoma cell line with ATCC Accession No. HB-12101, J415 produced by the hybridoma cell line with ATCC Accession No. HB-12109, J533 produced by the hybridoma cell line with ATCC Accession No. HB-12127, and J591 produced by the hybridoma cell line with ATCC Accession No. HB-12126. All of these are disclosed in U.S. Patent Nos. 6,107,090 and 6,136,311, which are incorporated by reference in their entireties. Most preferably, the murine monoclonal antibody is J591 produced by HB-12126, or the deimmunized J591 antibody described in U.S. Patent Nos. 7,045,605 and 7,514,078 to Bander et al., which are incorporated by reference in their entireties.

[0047] In some embodiments, the targeting moiety targets a HER receptor family member. An exemplary targeting moiety for a HER receptor family member is monoclonal antibody 4D5.

[0048] In certain embodiments, the targeting moiety is a peptide that binds to tumor-associated antigens. Exemplary peptides include, but are not limited to, glutamic acid-urea-lysine derivatives, such as 2(3-99S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid (ACUPA), which binds to FOLH1 / PSMA, somatostatin derivatives that bind to SSTR2, and Arg-Gly-Asp (RGD) peptides that bind to α-v / β-3 integrin.

[0049] Peptides used with the present disclosure may be obtained from natural sources by known isolation and purification protocols, synthesized by standard solid-phase or solution-phase peptide synthesis methods according to the peptide's known peptide sequence, or obtained from commercial preparations or peptide libraries. Peptides that exhibit the biological binding properties of the native peptide and retain the specific binding properties of the native peptide are included herein. As used herein, derivatives and analogs of peptides include modifications of the composition, identity, and derivatization of the individual amino acids of the peptide, provided that the peptide retains the specific binding properties of the native peptide. Examples of such modifications would include any amino acid modification, including D-stereoisomers, substitutions in the aromatic side chains of aromatic amino acids, derivatization of the amino or carboxyl group in the side chain of amino acids containing an amino or carboxyl group in the side chain, substitutions at the amino or carboxy terminus of the peptide, conjugation of the peptide to a second peptide or biologically active moiety, and cyclization of the peptide (G. Van Binst and D. Tourwe, "Backbone Modifications in Somatostatin Analogues: Relation Between Conformation and Activity", Peptide Research 5:8-13 (1992), which is incorporated by reference in its entirety).

[0050] As used herein, a "small molecule" is typically an organic, peptide, or non-peptide molecule having a molecular weight of less than 10,000 Da, preferably less than 5,000 Da, more preferably less than 1,000 Da, and most preferably less than 500 Da. This class of modulator includes chemically synthesized molecules, e.g., compounds derived from combinatorial chemical libraries.

[0051] In certain embodiments, targeting component is aptamer.Aptamer is a small single-stranded DNA oligonucleotide or RNA oligonucleotide that specifically binds to target molecule (for example, tumor-associated antigen) with high affinity and specificity.Aptamer is produced by using an in vitro selection process called enrichment in vitro (SELEX), which is described in Ellington et al., " In Vitro Selection of RNA Molecules That Bind Specific Ligands ", Nature 346:818-822 (1990) and Jayasena, " Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics ", Clin. Chem. 45:1628-1650 (1999), which are incorporated herein by reference in their entirety. Several aptamers have been developed that can target tumor-associated antigens, including, but not limited to, MUC1, HER2, HER3, EpCAM, NF-kB, PSMA, CD44, PD-1, CD137, CD134, PDGF, VEGF, and NCL (Jayasena, "Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics," Clin. Chem. 45:1628-1650 (1999)), which is incorporated by reference in its entirety.

[0052] As used herein, the term "enzyme" includes any enzyme, protein, or peptide that, when delivered to a tumor or tissue by a targeting moiety, catalyzes the conversion of the tumor or tissue to an incompatible allograft.

[0053] In one aspect, the enzyme is an enzyme involved in post-translational modification and is selected from the group consisting of transferases and glycosyltransferases.

[0054] A transferase is any one of a class of enzymes that transfers a particular functional group (e.g., a methyl group or a glycosyl group) from one molecule (called the donor) to another molecule (called the acceptor).

[0055] An exemplary group of transferases includes, but is not limited to, glycosyltransferases. Glycosyltransferases catalyze the stepwise addition of activated sugars (donor NDP-sugars) to proteins, glycoproteins, lipids, or glycolipids, or to the non-reducing end of a growing oligosaccharide (Lairson et al., "Glycosyltransferases: Structures, Functions, and Mechanisms," Annu. Rev. Biochem. 77:521-55 (2008)), which is incorporated herein by reference in its entirety. Glycosyltransferases are well known in the art.

[0056] Mammals utilize nine sugar nucleotide donors for glycosyltransferases: UDP-glucose, UDP-galactose, UDP-GlcNAc, UDP-GalNAc, UDP-xylose, UDP-glucuronic acid, GDP-mannose, GDP-fucose, and CMP-sialic acid.

[0057] For enzymatic saccharide synthesis involving glycosyltransferase reactions, glycosyltransferases can be cloned, i.e., isolated, from any source. Many cloned glycosyltransferases are known, as are their polynucleotide sequences (see, for example, "The WWW Guide To Cloned Glycosyltransferases," Taniguchi et al., 2002, Handbook of Glycosyltransferases and Related Genes, Springer, Tokyo, the entire contents of which are incorporated herein by reference). The amino acid sequences of glycosyltransferases and the nucleotide sequences encoding glycosyltransferases from which the amino acid sequences can be deduced are also well known in the art.

[0058] Glycosyltransferases that can be used in the methods of the present disclosure include, but are not limited to, galactosyltransferases, fucosyltransferases, glucosyltransferases, N-acetylgalactosaminyltransferases, N-acetylglucosaminyltransferases, glucuronyltransferases, sialyltransferases, mannosyltransferases, glucuronosyltransferases, galacturonosyltransferases, and oligoglycosyltransferases. Suitable glycosyltransferases include glycosyltransferases obtained from eukaryotes and prokaryotes.

[0059] Glycosyltransferases are crucial for the development of the ABO blood group antigen system. As previously mentioned, the ABO blood system is the primary antigen system important in blood transfusions and solid organ transplantation. This histo-blood group antigen (HBGA) system is controlled by the activity of GTA and / or GTB glycosyltransferases, which attach sugar residues (N-acetylgalactosamine or galactose) to a common substrate (H antigen). There are several phenotypic variants of this enzyme that either alter the carbohydrate attached (N-acetylgalactosamine (A) vs. galactose (B)) or cause a loss-of-function form of the enzyme that prevents modification of the H antigen (O). The A variant, A2, has reduced N-acetylgalactosamine activity and reduced levels of NAc-gal addition. These variants are currently distinguished by serology and by lectin binding (defining A1 vs. A2). Serology can detect modifications of the H antigen, or the presence of natural antibodies directed against A and / or B (e.g., individuals with a glycosylation pattern of B have antibodies directed against A).

[0060] In humans, the glycosyltransferase locus, referred to herein as the ABO locus or ABO glycosyltransferase locus, is located on chromosome 9 and contains seven exons spanning over 18 kb of genomic DNA. Exon 7 is the largest exon and contains the majority of the coding sequence. The ABO locus has three major allelic forms: A, B, and O. The A "allele" (also called A1 or A2) encodes a glycosyltransferase that enzymatically adds N-acetylgalactosamine to the D-galactose terminus of the H antigen, resulting in the so-called A antigen. The B allele encodes a glycosyltransferase that enzymatically adds D-galactose to the D-galactose terminus of the H antigen, thus creating the so-called B antigen. The O allele encodes a non-functional form of glycosyltransferase, resulting in an unmodified H antigen and the so-called O antigen phenotype.

[0061] At the genomic level, the ABO glycosyltransferase gene has many alleles (approximately 300). These natural allelic variants are described in Yip, "Sequence Variation at the Human ABO Locus," Ann. Hum. Genet. 66:1-27 (2002); Hakomori, "Antigen Structure and Genetic Basis of Histo-Blood Groups A, B, and O: Their Changes Associated with Human Cancer," Biochimica et Biophysica Acta 1473:247-266 (1999); Seto et al., "Sequential Interchange of Four Amino Acids from Blood Group B to Blood Group A Glycosyltransferase Boosts Catalytic Activity and Progressively Modifies Substrate Recognition in Human Recombinant Enzymes," J. Biol. Chem. 272:14133-14138 (1997), which are incorporated by reference in their entireties, and are contemplated for use in the bifunctional therapeutics of the present disclosure. The sequence encoding the catalytic site of the enzyme is located in exon 7 of the gene. Key amino acid residues 176, 235, 266, and 268 control the specificity of this active site. Furthermore, a common nucleotide deletion in exon 6 results in a stop codon that abolishes synthesis of the full-length glycosyltransferase, thereby resulting in an O or null phenotype.

[0062] Thus, in some embodiments, the glycosyltransferase is selected from the group consisting of glycosyltransferase A (α1-3-N-acetylgalactosaminlytransferase), glycosyltransferase B (α1-3-galactosyltransferase), α-gal-transferase, and glycosyltransferase A (Gly268Ala). Allelic variants of the foregoing are also contemplated.

[0063] In some embodiments, the glycosyltransferase used in the methods of the present disclosure is a fucosyltransferase.Fucosyltransferases are known to those skilled in the art.Exemplary fucosyltransferases include enzymes that transfer L-fucose from GDP-fucose to the hydroxy position of an acceptor sugar.Fucosyltransferases that transfer non-nucleotide sugars to acceptors are also useful in the present disclosure.

[0064] In some aspects, the glycosyltransferase is a humanized or deimmunized glycosyltransferase. Methods for humanizing or deimmunizing proteins are known in the art.

[0065] Thus, one aspect of the present disclosure relates to altering blood group antigen expression on tumors and / or the tumor blood supply by tumor-targeted glycosyltransferases, which, as noted above, effectively converts the tumor phenotype to that of an incompatible allograft or xenograft, thereby initiating hyperacute rejection.

[0066] The bifunctional therapeutic agents described herein may be formed such that the targeting moiety is a protein or peptide linked to an enzyme via a peptide bond.

[0067] In certain embodiments, a protein or peptide targeting component linked to an enzyme via a peptide bond may be referred to as a chimeric protein or a fusion protein. As used herein, the term "chimeric protein" or "fusion protein" refers to a polypeptide having a single continuous polypeptide chain, i.e., a series of consecutive amino acids linked by peptide bonds, or a series of covalently or non-covalently linked polypeptide chains (i.e., a polypeptide complex) comprising at least a portion of the full-length sequence of a first polypeptide sequence and at least a portion of the full-length sequence of a second polypeptide sequence, where the first and second polypeptides are different polypeptides. Chimeric polypeptides also include polypeptides comprising two or more non-contiguous portions derived from the same polypeptide. Chimeric polypeptides or proteins also include polypeptides with at least one substitution, where a chimeric polypeptide comprises a first polypeptide sequence in which a portion of the first polypeptide sequence is replaced by a portion of the second polypeptide sequence. The series of polypeptide chains may be covalently linked using a suitable biochemical linker or disulfide bond.

[0068] The linkage between the targeting moiety and the enzyme may also be prepared using chemical bonding (Brennan et al., "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments," Science 229:81-3 (1985), which is incorporated herein by reference in its entirety) or chemical coupling (Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive With Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene," J. Exp. Med. 175:217-225 (1992), which is incorporated herein by reference in its entirety).

[0069] In other embodiments, the targeting moiety and enzyme may be linked via non-covalent bonds, including, but not limited to, hydrogen bonds, ionic bonds, van der Waals forces, and hydrophobic interactions.

[0070] Therefore, the fusion or linkage between targeting moieties (e.g., antibodies) and enzymes can be achieved by conventional covalent or ionic bonds, genetically engineered protein fusion, or heterobifunctional cross-linkers, such as carbodiimides, glutaraldehyde, etc. Conventional inert linker sequences (e.g., peptide linkers) that simply provide a desired amount of space between targeting moieties and enzymes can also be used. The design of such linkers is well known to those skilled in the art and is described, for example, in U.S. Patent Nos. 8,580,922; 5,525,491; and 6,165,476, the entire contents of which are incorporated herein by reference. A variety of coupling or cross-linking agents can be used for covalent protein conjugation. Examples of cross-linking agents include protein A, carbodiimide, N-succinimidyl-S-acetyl-thioacetate (SATA), 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB), o-phenylenedimaleimide (oPDM), N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), and sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) (see, e.g., Karpovsky et al., “Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fc Gamma Receptor Antibodies,” J. Exp. Med. 160(6):1686-701 (1984); Liu et al., “Heteroantibody Duplexes Target Cells for Lysis by Cytotoxic T Lymphocytes,” Proc. Natl. Acad. Sci. USA 82(24):8648-52 (1985).Other methods include those described in Paulus, Behring Ins Mitt No. 78, 118-132 (1985); Brennan et al., "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments," Science 229:81-83 (1985); Glennie et al., "Preparation and Performance of Bispecific F(ab' gamma)2 Antibody Containing Thioether-Linked Fab' Gamma Fragments," J. Immunol. 139:2367-2375 (1987), the entire contents of which are incorporated by reference herein.

[0071] Many other linkers can be used to connect targeting moieties to enzymes.For example, disulfide bonds can be used as described in Saito et al., Adv. Drug Delivery Reviews 55:199-215 (2003), the entirety of which is incorporated herein by reference.Linkers that are sensitive to the low pH found in endosomes or tumor environments, including hydrazones, ketals, and / or aconitic acids, can also be used.Hybrid linkers, for example, linkers with two or more potential cleavage sites, for example, disulfides and hydrazones, can also be used.Peptidase-sensitive linkers, for example, linkers that are sensitive to cleavage by tumor-specific peptidases, for example, PSA, can also be used.PEG linkers can also be used (Wiiest et al., Oncogene 21:4257-4265 (2002), the entirety of which is incorporated herein by reference). Exemplary linkers include hydrazone and disulfide hybrid linkers (see Hamann et al., Bioconjugate Chem. 13:47-58 (2002); Hamann et al., Bioconjug Chem. 13(1):40-6 (2002), which are incorporated by reference in their entirety); SPP (Immunogen); and various linkers available from Pierce Biotechnology, Inc. In some embodiments, the linker is SSP (a disulfide linker, available from Immunogen), and the linker to antibody ratio can be, for example, 7:1 to 4:1. Various spacer and linker sequences are known in the art and are described in Chen et al., "Fusion Protein Linkers: Property, Design and Functionality," Adv. Drug Deliv. Rev. 65(10):1357-69 (2013), which is incorporated by reference in its entirety.

[0072] The term "peptide linker" or spacer refers to a short peptide fragment that joins or connects the targeting component and the enzymatic portion of a polypeptide of a bifunctional therapeutic. The linker is preferably composed of amino acids linked by peptide bonds. For example, a peptide linker may contain small or hydrophilic amino acid residues (e.g., glycine, serine, threonine, proline, aspartic acid, asparagine, etc.). For example, a peptide linker is a peptide having an amino acid sequence at least 5 amino acids in length, or about 5 to about 100 amino acids in length, or about 10 to 50 amino acids in length, or about 10 to 15 amino acids in length.

[0073] In one example, the linker is made up of a majority of sterically hindered amino acids, such as glycine and alanine. Thus, in a further example, the linker is polyglycine, polyalanine, or polyserine.

[0074] Those skilled in the art will appreciate that many commonly used peptide linkers can be used in the embodiments of the present disclosure. In certain embodiments, a short peptide linker may contain repeat units to increase the linker length, such as a two-repeat linker, a three-repeat linker, or a four-repeat linker. In one example, the linker has the formula (Gly-Gly-Gly-Gly-Ser) n (SEQ ID NO:1) or comprising the formula (Ser-Gly-Gly-Gly-Gly) n Ser (SEQ ID NO:2), where n is a number from 3 to 6. In some embodiments, the linker is a (G4S)3 linker (SEQ ID NO:67).

[0075] Non-peptide linkers or spacers are also possible, for example, alkyl linkers, such as -NH-(CH) where s=2-20. s-C(O)- can be used. These alkyl linkers can be further substituted with any non-sterically hindering group, such as lower alkyl (e.g., C1-C6), lower acyl, halogen (e.g., Cl, Br), CN, NH2, phenyl, etc. An exemplary non-peptide linker is a PEG linker or spacer having a molecular weight of 100 to 5000 kD, preferably 1000 to 2000 kD, more preferably 1500 kD.

[0076] A bifunctional therapeutic according to the present disclosure may be N-terminally connected to its C-terminus. N-terminus and C-terminus are used herein to refer to the N-terminal and C-terminal regions or portions, respectively, of a bifunctional therapeutic protein of the present disclosure. In some embodiments of the present disclosure, the C-terminal and N-terminal portions of a bifunctional therapeutic of the present disclosure are contiguously joined. In other embodiments, the C-terminal and N-terminal portions of a bifunctional therapeutic of the present disclosure are connected by an intervening spacer. In one embodiment, the spacer may be a polypeptide sequence of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acid residues. In some embodiments, the C-terminal and / or N-terminal portions of a bifunctional therapeutic of the present disclosure may include an additional moiety connected to the C-terminal and / or N-terminal residue, respectively, of a chimeric protein of the present disclosure. In some embodiments, the additional moiety can be a polypeptide sequence of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more amino acid residues. In some embodiments, the C-terminal and / or N-terminal moieties having such additional moieties maintain the activity of the corresponding native N-terminal moiety of the targeting component and / or C-terminal moiety of the enzyme, respectively. In some embodiments, the N-terminal and / or C-terminal moieties having such additional moieties have improved and / or prolonged activity compared to the corresponding native N-terminal moiety of the targeting component and / or C-terminal moiety of the enzyme, respectively. In other embodiments, the C-terminal and / or N-terminal moieties of the bifunctional therapeutic of the present disclosure do not include any additional moieties attached to the C-terminal and / or N-terminal residues of the chimeric proteins of the present disclosure, respectively.

[0077] In one embodiment, the N-terminal region comprises a targeting moiety. In certain embodiments, the targeting moiety is an antibody or antigen-binding portion thereof, including, but not limited to, a monomeric single-chain antibody, a Fab fragment, a Fab'2, an scFv, and other antibody fragment derivatives, such as a minibody, a diabody, and a triabody. The antibody or antigen-binding fragment may retain or lack the FcRn-binding domain.

[0078] In one embodiment, the N-terminal region comprises a human J591 heavy chain and has the amino acid sequence of SEQ ID NO:3 (GenBank Accession No. CCA78124.1, herein incorporated by reference in its entirety), or a portion thereof, as follows: TIFF2023551305000002.tif18137

[0079] In another embodiment, the N-terminal region comprises a human J591 light chain and has the amino acid sequence of SEQ ID NO:4 (GenBank Accession No. CCA78125.1, herein incorporated by reference in its entirety), or a portion thereof, as follows: TIFF2023551305000003.tif17138

[0080] In another embodiment, the N-terminal region comprises a human 4D5 heavy chain and has the amino acid sequence of SEQ ID NO:5, or a portion thereof, as follows: TIFF2023551305000004.tif61138

[0081] In another embodiment, the N-terminal region comprises the human 4D5 light chain and has the amino acid sequence of SEQ ID NO:6, or a portion thereof, as follows: TIFF2023551305000005.tif32138

[0082] In accordance with the above, in some embodiments the C-terminal region comprises an enzyme.

[0083] In one aspect, the C-terminal region comprises the catalytic domain of glycosyltransferase B (GTB) and has the amino acid sequence of SEQ ID NO:7 (GenBank Accession No. AM423112.1, which is incorporated by reference in its entirety herein), or a portion thereof, as follows: TIFF2023551305000006.tif53138

[0084] In another embodiment, the C-terminal region contains a "cisA,B" sequence resulting in a hybrid sequence of GTB and GTA and has the amino acid sequence of SEQ ID NO:8 (GenBank Accession No. ABL75287.1, the entirety of which is incorporated by reference herein) or a portion thereof, as follows: TIFF2023551305000007.tif32137

[0085] In another embodiment, the C-terminal region comprises the catalytic domain of glycosyltransferase A (GTA) and has the amino acid sequence of SEQ ID NO:9 (GenBank Accession No. AFB74122.1, herein incorporated by reference in its entirety), or a portion thereof, as follows: TIFF2023551305000008.tif53138

[0086] In certain embodiments, tumors bearing tumor-associated antigens express the H antigen. As used herein, "H antigen" refers to an oligosaccharide chain having a terminal disaccharide fucose-galactose, in which the fucose has an α-(1-2)-linkage. The H antigen is produced by fucosyltransferase and is the building block for producing the A or B antigens in the ABO blood group system.

[0087] Accordingly, the present disclosure also relates to a method of treating cancer, comprising selecting a subject having cancer and providing a bifunctional therapeutic according to the present disclosure, wherein the bifunctional therapeutic is administered to the selected subject under conditions effective to treat the cancer.

[0088] The bifunctional therapeutic agents described herein can be used to treat prostate tumors, adrenocortical carcinoma tumors, anal tumors, appendix tumors, astrocytoma (pediatric cerebellar or cerebral), basal cell carcinoma, bile duct tumors, bladder tumors, bone tumors, osteosarcoma / malignant fibrous histiocytoma, brain stem glioma, ependymoma, medulloblastoma, breast tumors, bronchial adenoma / carcinoid, Burkitt's lymphoma, carcinoid tumor, cervical tumors, pediatric tumors, chondrosarcoma, colon tumors, cutaneous T-cell lymphoma, desmoplastic small round cell tumor, endometrial tumors, esophageal tumors, Ewing's sarcoma, retinoblastoma, gallbladder tumors, gastric (stomach) tumors, gastrointestinal stromal tumors, germ cell tumors, gestational trophoblastic tumors, head and neck tumors, cardiac tumors, hepatocellular (liver) tumors, Hodgkin's disease Virtually any H antigen-expressing tumor can be treated, including, but not limited to, lymphoma, hypopharyngeal tumor, islet cell carcinoma (endocrine pancreas), Kaposi's sarcoma, kidney tumor, laryngeal tumor, lip and oral cavity tumor, non-small cell lung tumor, cell lung tumor, lymphoma, melanoma, Merkel cell tumor, mesothelioma, multiple endocrine neoplasia, multiple myeloma, nasopharyngeal tumor, neuroblastoma, oligodendroglioma, oral cavity tumor, oropharyngeal tumor, ovarian tumor, pancreatic tumor, pleuropulmonary, primary central nervous system lymphoma, retinoblastoma, rhabdomyosarcoma, salivary gland tumor, soft tissue sarcoma, uterine sarcoma, skin tumor (non-melanoma), small intestine tumor, squamous cell carcinoma, gastric tumor, testicular tumor, pharyngeal tumor, thymoma and thymic carcinoma, thyroid tumor, trophoblastic tumor, and urethral tumor.

[0089] Some cancers, including but not limited to hematopoietic or lymphoid cancers, mesodermal cancers, sarcomas, and neuroectodermal cancers, may not express the H antigen. This can be easily confirmed by flow cytometry or immunohistochemistry of tumor samples using Ulex lectin binding, which reveals the presence or absence of H. When H is absent, treatment with the present application can be accomplished in two ways. As previously described, a targeted fucosyltransferase may be used to add the H antigen before or simultaneously with the targeted glycosyltransferase. Alternatively, the α-galT enzyme, which can add terminal galactose and does not require the presence of 1,2 fucose (H antigen), may be targeted.

[0090] In one embodiment, the targeting component of the bifunctional therapeutic agent targets the PSMA receptor on tumor vascular endothelium. PSMA expression has been reported in tumor neovasculature in various tumors, but is not present in normal tissue vasculature. Exemplary tissue types with PSMA-positive vascular endothelium include, but are not limited to, kidney, lung, colon, stomach, breast, brain, pancreas, liver, bladder, esophagus, adrenal gland, head and neck, melanoma, and brain tumors. Other embodiments include targeting PSMA expressed on the surface of prostate cancer cells, targeting HER2 on the surface of breast and other HER2-positive cancers, targeting CD19 on the surface of B-cell lineage cancers, and targeting CEA on the surface of colorectal cancer. Other applicable targets are described above.

[0091] Some aspects of the present disclosure relate to bifunctional therapeutics comprising a targeting moiety that comprises the amino acid sequences of one, two, three, four, five, or six CDRs as set forth herein in Tables 1 and 2. In some embodiments, the targeting moiety comprises a modified amino acid sequence, wherein the modified amino acid sequence has at least 80% sequence identity to any one, two, three, four, five, or six of the CDR sequences set forth in Tables 1 and 2.

[0092] Table 1. Heavy chain CDR sequences of suitable targeting moiety antibodies TIFF2023551305000009.tif54163 * See US Patent Application Publication No. 2006 / 0088539, Figures 2A-2B, which is incorporated by reference herein in its entirety. ** See US Pat. No. 5,821,337, Figures 1A-1B, which is incorporated by reference herein in its entirety. *** See EP2059536; PCT / US2007 / 075932, which are incorporated by reference herein in their entireties.

[0093] Table 2: Light chain CDR sequences of suitable targeting moiety antibodies TIFF2023551305000010.tif55158 * See US Patent Application Publication No. 2006 / 0088539, Figures 2A-2B, which is incorporated by reference herein in its entirety. ** See US Pat. No. 5,821,337, Figures 1A-1B, which is incorporated by reference herein in its entirety. *** See EP2059536; PCT / US2007 / 075932, which are incorporated by reference herein in their entireties.

[0094] In some embodiments, the heavy and / or light chain variable regions of the antibody-based molecules described herein further comprise human or humanized immunoglobulin heavy and / or light chain framework regions, respectively.

[0095] In some embodiments of the present disclosure, the targeting moiety comprises one or two of the sequences shown in Table 3 herein. In some embodiments, the targeting moiety comprises a modified amino acid sequence, wherein the modified amino acid sequence has at least 80% sequence identity to any one or two of the sequences shown in Table 3.

[0096] Table 3: Antibody variable heavy chain (V H ) and variable light chain (VL ) Antibody sequence TIFF2023551305000011.tif148162 † Complementarity determining regions are shown in bold type. * See US Patent Application Publication No. 2006 / 0088539, Figures 2A-2B, which is incorporated by reference herein in its entirety. ** See US Pat. No. 5,821,337, Figures 1A-1B, which is incorporated by reference herein in its entirety. *** See EP2059536; PCT / US2007 / 075932, which are incorporated by reference herein in their entireties.

[0097] Suitable amino acid modifications to the heavy and / or light chain CDR sequences of the targeting domains disclosed herein include, for example, conservative substitutions or functionally equivalent amino acid residue substitutions that result in variant CDR sequences with similar or improved binding characteristics to those of the CDR sequences disclosed herein, as described above. Included in the present disclosure are the CDRs of Tables 1 and 2 that contain one, two, three, four, five, or more amino acid substitutions (depending on the length of the CDR) that maintain or improve binding of the antibody to its target (e.g., PSMA, CD14, HER2). The resulting modified CDRs are at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% similar in sequence to the CDRs of Tables 1 and 2. Suitable amino acid modifications to the heavy chain CDR sequences in Table 1 and / or the light chain CDR sequences in Tables 1 and 2 include, for example, conservative substitutions or functionally equivalent amino acid residue substitutions that result in variant CDR sequences with similar or improved binding characteristics to those of the CDR sequences in Tables 1 and 2. Conservative substitutions are those that occur within a family of amino acids that are related in their side chains. Genetically encoded amino acids can be divided into four families: (1) acidic (aspartic acid, glutamic acid); (2) basic (lysine, arginine, histidine); (3) nonpolar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan); and (4) uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine). Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. Alternatively, the amino acid repertoire can be divided into: (1) acidic (aspartic acid, glutamic acid); (2) basic (lysine, arginine, histidine); and (3) aliphatic (glycine, alanine, valine, leucine, isoleucine, serine, threonine).Serine and threonine are optionally classified separately as aliphatic-hydroxyl; (4) aromatic (phenylalanine, tyrosine, tryptophan); (5) amide (asparagine, glutamine); and (6) sulfur-containing (cysteine ​​and methionine) (Stryer (ed.), Biochemistry, 2nd ed., W.H. Freeman and Co., 1981, the entire contents of which are incorporated by reference herein). Non-conservative substitutions can also be made to the heavy chain CDR sequences in Table 1 and the light chain CDR sequences in Table 2. Non-conservative substitutions involve replacing one or more amino acid residues in a CDR with one or more amino acid residues from a different amino acid class to improve or enhance the binding properties of the CDR. The amino acid sequences of the heavy chain variable region CDRs in Table 1 and / or the amino acid sequences of the light chain variable region CDRs in Table 2 may further contain one or more internal neutral amino acid insertions or deletions that maintain or improve target (e.g., PSMA, CD19, HER2) binding.

[0098] In some embodiments, the V of the targeting domain H The chain is V shown in Table 3 above. H or any one of the VH amino acid sequences listed in Table 3, or an amino acid sequence at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identical to any one of the VH amino acid sequences listed in Table 3. For example, a targeting domain described herein may comprise: (i) a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:30; (ii) a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:32; or (iii) a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:34.

[0099] In some embodiments, the V of the targeting domain L The chain is V shown in Table 3 above. L Any one of the amino acid sequences or V listed in Table 3 Land (iii) a light chain variable region comprising an amino acid sequence at least 80% identical to any one of SEQ ID NO:33.

[0100] In some embodiments, the targeting domain disclosed herein comprises: (i) a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:30 and a light chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:29; (ii) a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:32 and a light chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:31; or (iii) a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:33 and a light chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:32.

[0101] The targeting domains of the present disclosure may be described or specified in terms of binding affinity. Thus, in some embodiments, the targeting domains of the present disclosure have a dissociation constant or K of less than 1 μM, 500 nM, 250 nM, 200 nM, 100 nM, 50 nM, 40 nM, 30 nM, 25 nM, 20 nM, 15 nM, 14 nM, 13 nM, 12 nM, 11 nM, 10 nM, 9 nM, 8 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM. D The targeting domain comprises:

[0102] Some aspects of the present disclosure relate to a bifunctional therapeutic agent for treating cancer, comprising a targeting moiety that targets the prostate-specific membrane antigen (PSMA) / folate hydrolase 1 (FOLH1) receptor, and a glycosyltransferase that, when delivered to a tumor by the targeting moiety, enzymatically converts the tumor phenotype to that of an incompatible allograft or xenograft, wherein the glycosyltransferase is linked to the targeting moiety. This aspect of the present disclosure is useful in treating subjects with prostate cancer.

[0103] In some embodiments, the targeting moiety comprises a heavy chain variable region, the heavy chain variable region comprising: a complementarity determining region 1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO:10 or a modified amino acid sequence of SEQ ID NO:10, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:10; a complementarity determining region 2 (CDR-H2) comprising the amino acid sequence of SEQ ID NO:13 or a modified amino acid sequence of SEQ ID NO:13, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:13; and a complementarity determining region 3 (CDR-H3) comprising the amino acid sequence of SEQ ID NO:16 or a modified amino acid sequence of SEQ ID NO:16, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:16. It contains a complementarity determining region 3 (CDR-H3) that has at least 80% sequence identity to NO: 16. The sequences of the heavy chain CDR sequences are shown in Table 1 above.

[0104] In some embodiments, the targeting moiety comprises a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:28 (Table 3 above).

[0105] The targeting moiety may further comprise a light chain variable region, the light chain variable region comprising: a complementarity determining region 1 (CDR-L1) having the amino acid sequence of SEQ ID NO:19 or a modified amino acid sequence of SEQ ID NO:19, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:19; a complementarity determining region 2 (CDR-L2) having the amino acid sequence of SEQ ID NO:22 or a modified amino acid sequence of SEQ ID NO:22, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:22; and a complementarity determining region 3 (CDR-L3) having the amino acid sequence of SEQ ID NO:25 or a modified amino acid sequence of SEQ ID NO:25, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:22. It contains a complementarity determining region 3 (CDR-L3) that has at least 80% sequence identity to NO:25. The sequences of the light chain CDR sequences are shown in Table 2 above.

[0106] In some embodiments, the light chain variable region comprises an amino acid sequence at least 80% identical to SEQ ID NO:29 (Table 3 above).

[0107] In some embodiments, the targeting moiety comprises a heavy chain variable region comprising CDR-H1 of SEQ ID NO:10, CDR-H2 of SEQ ID NO:13, and CDR-H3 of SEQ ID NO:16, and a light chain variable region comprising CDR-L1 of SEQ ID NO:19, CDR-L2 of SEQ ID NO:22, and CDR-L3 of SEQ ID NO:25.

[0108] In some embodiments, the targeting moiety comprises a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:28 and a light chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:29 (Table 3).

[0109] In some embodiments, the targeting moiety optionally further comprises a signaling peptide, wherein the signaling peptide has the sequence of amino acids 1-19 of SEQ ID NO:34.

[0110] In some embodiments, the glycosyltransferase is selected from the group consisting of glycosyltransferase A (α1-3-N-acetylgalactosaminyltransferase) and glycosyltransferase B (α1-3-galactosyltransferase).

[0111] In some embodiments, the glycosyltransferase is glycosyltransferase A (“GTA”) and has the amino acid sequence of SEQ ID NO:64, or a portion thereof, as follows: TIFF2023551305000012.tif32163

[0112] In some embodiments, the glycosyltransferase is glycosyltransferase B (“GTB”) and has the amino acid sequence of SEQ ID NO:65, or a portion thereof, as follows: TIFF2023551305000013.tif32163

[0113] Additional suitable glycosylases are described below. In some embodiments, the glycosyltransferase is marmoset alpha-1,3 galactosyltransferase (aa90-376), having the amino acid sequence of SEQ ID NO:66, or a portion thereof, as follows: TIFF2023551305000014.tif32163

[0114] In some embodiments, the bifunctional therapeutic is selected from the group consisting of: (i) a first protein comprising the amino acid sequence of SEQ ID NO:34 or SEQ ID NO:35 and a second protein comprising the amino acid sequence of SEQ ID NO:36; (ii) a first protein comprising the amino acid sequence of SEQ ID NO:37 or SEQ ID NO:38 and a second protein comprising the amino acid sequence of SEQ ID NO:39; (iii) a first protein comprising the amino acid sequence of SEQ ID NO:40 or SEQ ID NO:41 and a second protein comprising the amino acid sequence of SEQ ID NO:42; (iv) a first protein comprising the amino acid sequence of SEQ ID NO:43 or SEQ ID NO:44 and a second protein comprising the amino acid sequence of SEQ ID NO:45; (v) the amino acid sequence of SEQ ID NO:46; (vi) the amino acid sequence of SEQ ID NO:47; (vii) the amino acid sequence of SEQ ID NO:48; or (viii) a first protein comprising the amino acid sequence of SEQ ID NO:49 or SEQ ID NO:50; The amino acid sequence of NO:49 (Table 4) is included.

[0115] Table 4: J591 bifunctional therapeutic protein sequence TIFF2023551305000015.tif238163TIFF2023551305000016.tif235163TIFF2023551305000017.tif249163TIFF2023551305000018.tif242163 TIFF2023551305000019.tif249163TIFF2023551305000020.tif249163TIFF2023551305000021.tif249163TIFF2023551305000022.tif234163

[0116] In some embodiments, the bifunctional therapeutic comprises a first protein comprising the amino acid sequence from positions 20 to 770 of SEQ ID NO:34 or SEQ ID NO:35 and a second protein comprising the amino acid sequence from positions 20 to 233 of SEQ ID NO:36.

[0117] In some embodiments, the bifunctional therapeutic comprises a first protein comprising the amino acid sequence from positions 20 to 540 of SEQ ID NO:37 or SEQ ID NO:38 and a second protein comprising the amino acid sequence from positions 20 to 233 of SEQ ID NO:39, and optionally, the bifunctional therapeutic comprises a first portion comprising the amino acid sequence from positions 20 to 558 of SEQ ID NO:37 or SEQ ID NO:38.

[0118] In some embodiments, the bifunctional therapeutic comprises a first protein comprising the amino acid sequence of SEQ ID NO:40 or SEQ ID NO:41 and a second protein comprising the amino acid sequence of positions 1-214 of SEQ ID NO:42.

[0119] In some embodiments, the bifunctional therapeutic comprises a first protein comprising the amino acid sequence from positions 20 to 831 of SEQ ID NO:43 or SEQ ID NO:44 and a second protein comprising the amino acid sequence from positions 1 to 214 of SEQ ID NO:45.

[0120] In some embodiments, the bifunctional therapeutic comprises the amino acid sequence from positions 1 to 767 of SEQ ID NO:46 or SEQ ID NO:47.

[0121] In some embodiments, the bifunctional therapeutic comprises the amino acid sequence from positions 20 to 591 of SEQ ID NO:48 or SEQ ID NO:49, and optionally, the bifunctional therapeutic comprises the sequence from positions 20 to 597 of SEQ ID NO:37 or SEQ ID NO:38.

[0122] Another aspect of the present disclosure relates to a bifunctional therapeutic for treating cancer, comprising a targeting moiety that targets a human epidermal growth factor receptor (HER) family member and a glycosyltransferase linked to the targeting moiety that, when delivered to a tumor by the targeting moiety, enzymatically converts the tumor phenotype to that of an incompatible allograft or xenograft. This aspect of the disclosure is useful in treating subjects with breast cancer or any HER2-expressing cancer.

[0123] In some embodiments, the targeting moiety comprises a heavy chain variable region comprising: a complementarity determining region 1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO:11 or a modified amino acid sequence of SEQ ID NO:11, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:11; a complementarity determining region 2 (CDR-H2) comprising the amino acid sequence of SEQ ID NO:14 or a modified amino acid sequence of SEQ ID NO:14, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:14; and a complementarity determining region 3 (CDR-H3) comprising the amino acid sequence of SEQ ID NO:17 or a modified amino acid sequence of SEQ ID NO:17, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:17. It contains a complementarity determining region 3 (CDR-H3) that has at least 80% sequence identity to NO: 17. The sequences of the heavy chain CDR sequences are shown in Table 1 above.

[0124] In some embodiments, the targeting moiety comprises a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:30 (Table 3 above).

[0125] The targeting moiety may further comprise a light chain variable region, the light chain variable region comprising: a complementarity determining region 1 (CDR-L1) having the amino acid sequence of SEQ ID NO:20 or a modified amino acid sequence of SEQ ID NO:20, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:20; a complementarity determining region 2 (CDR-L2) having the amino acid sequence of SEQ ID NO:23 or a modified amino acid sequence of SEQ ID NO:23, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:23; and a complementarity determining region 3 (CDR-L3) having the amino acid sequence of SEQ ID NO:26 or a modified amino acid sequence of SEQ ID NO:26, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:26. It contains a complementarity determining region 3 (CDR-L3) that has at least 80% sequence identity to NO: 26. The sequences of the light chain CDR sequences are shown in Table 2 above.

[0126] In some embodiments, the light chain variable region comprises an amino acid sequence at least 80% identical to SEQ ID NO:31 (Table 3 above).

[0127] In some embodiments, the targeting moiety comprises a heavy chain variable region comprising CDR-H1 of SEQ ID NO:11, CDR-H2 of SEQ ID NO:14, and CDR-H3 of SEQ ID NO:17, and a light chain variable region comprising CDR-L1 of SEQ ID NO:20, CDR-L2 of SEQ ID NO:23, and CDR-L3 of SEQ ID NO:26.

[0128] In some embodiments, the targeting moiety comprises a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:30 and a light chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:31 (Table 3).

[0129] In some embodiments, the targeting moiety further comprises a signaling peptide, optionally, the signaling peptide has the sequence of amino acids 1-19 of SEQ ID NO:50.

[0130] Suitable glycosyltransferases are detailed below.

[0131] In some embodiments, the glycosyltransferase is selected from the group consisting of glycosyltransferase A (α1-3-N-acetylgalactosaminyltransferase) and glycosyltransferase B (α1-3-galactosyltransferase).

[0132] In some embodiments, the bifunctional therapeutic comprises (i) a first protein comprising the amino acid sequence of SEQ ID NO:50 or SEQ ID NO:51 and a second protein comprising the amino acid sequence of SEQ ID NO:52; (ii) a first protein comprising the amino acid sequence of SEQ ID NO:53 or SEQ ID NO:54 and a second protein comprising the amino acid sequence of SEQ ID NO:55; (iii) a first protein comprising the amino acid sequence of SEQ ID NO:56 or SEQ ID NO:57 and a second protein comprising the amino acid sequence of SEQ ID NO:58; (iv) the amino acid sequence of SEQ ID NO:59; (v) the amino acid sequence of SEQ ID NO:60; (vi) the amino acid sequence of SEQ ID NO:61; or (vii) the amino acid sequence of SEQ ID NO:62 (Table 5).

[0133] Table 5: 4D5 bifunctional therapeutic protein sequences TIFF2023551305000023.tif143163TIFF2023551305000024.tif235163TIFF2023551305000025.tif249163TIFF20235513050 00026.tif242163TIFF2023551305000027.tif246163TIFF2023551305000028.tif235163TIFF2023551305000029.tif136163

[0134] In some embodiments, the bifunctional therapeutic comprises a first protein comprising the amino acid sequence from positions 20 to 774 of SEQ ID NO:50 or SEQ ID NO:51 and a second protein comprising the amino acid sequence from positions 20 to 233 of SEQ ID NO:52.

[0135] In some embodiments, the bifunctional therapeutic comprises a first protein comprising the amino acid sequence from positions 20-563 of SEQ ID NO:53 or SEQ ID NO:54 and a second protein comprising the amino acid sequence from positions 20-233 of SEQ ID NO:55, and optionally, the bifunctional therapeutic comprises a first portion comprising the amino acid sequence from positions 20-569 of SEQ ID NO:53 or SEQ ID NO:54.

[0136] In some embodiments, the bifunctional therapeutic comprises a first protein comprising the amino acid sequence of SEQ ID NO:56 or SEQ ID NO:57 and a second protein comprising the amino acid sequence of positions 1-214 of SEQ ID NO:58.

[0137] In some embodiments, the bifunctional therapeutic comprises the amino acid sequence from positions 1 to 555 of SEQ ID NO:59 or SEQ ID NO:60.

[0138] In some embodiments, the bifunctional therapeutic comprises the amino acid sequence from positions 20 to 593 of SEQ ID NO:61 or SEQ ID NO:62, and optionally, the bifunctional therapeutic comprises the sequence from positions 20 to 599 of SEQ ID NO:61 or SEQ ID NO:62.

[0139] Another aspect of the present disclosure relates to a bifunctional therapeutic agent for treating cancer, comprising a targeting moiety that targets CD19 and a glycosyltransferase linked to the targeting moiety that, when delivered to a tumor by the targeting moiety, enzymatically converts the tumor phenotype to that of an incompatible allograft or xenograft. This aspect of the disclosure is useful in treating subjects in need of eliminating B cells or B cell activity. In some embodiments, this aspect of the disclosure is useful for treating lymphoma (e.g., B cell lymphoma), B cell leukemia, and / or autoimmune disease.

[0140] In some embodiments, the targeting moiety comprises a heavy chain variable region comprising: a complementarity determining region 1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO:12 or a modified amino acid sequence of SEQ ID NO:12, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:12; a complementarity determining region 2 (CDR-H2) comprising the amino acid sequence of SEQ ID NO:15 or a modified amino acid sequence of SEQ ID NO:15, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:15; and a complementarity determining region 3 (CDR-H3) comprising the amino acid sequence of SEQ ID NO:18 or a modified amino acid sequence of SEQ ID NO:18, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:15. It contains a complementarity determining region 3 (CDR-H3) that has at least 80% sequence identity to NO: 18. The sequences of the heavy chain CDR sequences are shown in Table 1 above.

[0141] In some embodiments, the targeting moiety comprises a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:32 (Table 3 above).

[0142] The targeting moiety may further comprise a light chain variable region, the light chain variable region comprising: a complementarity determining region 1 (CDR-L1) having the amino acid sequence of SEQ ID NO:21 or a modified amino acid sequence of SEQ ID NO:21, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:21; a complementarity determining region 2 (CDR-L2) having the amino acid sequence of SEQ ID NO:24 or a modified amino acid sequence of SEQ ID NO:24, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:24; and a complementarity determining region 3 (CDR-L3) having the amino acid sequence of SEQ ID NO:27 or a modified amino acid sequence of SEQ ID NO:27, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:27. It contains a complementarity determining region 3 (CDR-L3) that has at least 80% sequence identity to NO: 27. The sequences of the light chain CDR sequences are shown in Table 2 above.

[0143] In some embodiments, the light chain variable region comprises an amino acid sequence at least 80% identical to SEQ ID NO:32 (Table 3 above).

[0144] In some embodiments, the targeting component comprises a heavy chain variable region comprising CDR-H1 of SEQ ID NO:12, CDR-H2 of SEQ ID NO:15, and CDR-H3 of SEQ ID NO:18, and a light chain variable region comprising CDR-L1 of SEQ ID NO:21, CDR-L2 of SEQ ID NO:24, and CDR-L3 of SEQ ID NO:27.

[0145] In some embodiments, the targeting moiety comprises a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:32 and a light chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:33 (Table 3).

[0146] In some embodiments, the targeting moiety further comprises a signaling peptide, optionally, the signaling peptide has the sequence of amino acids 1-19 of SEQ ID NO:63.

[0147] Suitable glycosyltransferases are described in more detail below.

[0148] In some embodiments, the glycosyltransferase is selected from the group consisting of glycosyltransferase A (α1-3-N-acetylgalactosaminyltransferase) and glycosyltransferase B (α1-3-galactosyltransferase).

[0149] In some embodiments, the glycosyltransferase is marmoset alpha-1,3 galactosyltransferase (aa90-376) having the sequence of SEQ ID NO:66.

[0150] In some embodiments, the bifunctional therapeutic comprises the amino acid sequence of SEQ ID NO:63 (Table 6).

[0151] Table 6. Obexelimab bifunctional therapeutic protein sequence TIFF2023551305000030.tif153163

[0152] In some embodiments, the bifunctional therapeutic comprises the amino acid sequence from positions 20 to 584 of SEQ ID NO:63, the amino acid sequence from positions 20 to 578 of SEQ ID NO:63, the amino acid sequence from positions 20 to 287 of SEQ ID NO:63, the amino acid sequence from positions 20 to 272 of SEQ ID NO:63, the amino acid sequence from positions 20 to 160 of SEQ ID NO:63, or the amino acid sequence from positions 20 to 140 of SEQ ID NO:63.

[0153] It is understood that the exact dosage of the bifunctional therapeutic agent of the present disclosure will be selected by the individual physician in consideration of the patient to be treated. Generally, dosage and administration are adjusted to provide an effective amount of the drug to the patient being treated. As used herein, the "effective amount" of a bifunctional therapeutic agent refers to the amount necessary to induce a desired biological response. As will be understood by those skilled in the art, the effective amount of a bifunctional therapeutic agent of the present disclosure may vary depending on factors such as the desired biological endpoint, the drug to be delivered, the target tissue, the route of administration, etc. For example, an effective amount of a bifunctional therapeutic agent may be an amount that reduces tumor size by a desired amount over a desired period of time. Additional factors that may be considered include the severity of the disease state; the age, weight, and sex of the patient being treated; diet, time and frequency of administration; drug combinations; reaction sensitivities; and tolerance / response to therapy.

[0154] An "effective amount" can also be a "prophylactically effective amount," which refers to the amount of a bifunctional therapeutic described herein that, upon single or multiple administrations to a subject, is effective in preventing or delaying the onset or recurrence of a disorder, e.g., cancer, from occurring or in treating a symptom thereof.

[0155] Generally, the dose may be about 25% to about 100% of the maximum tolerated dose (MTD) of the bifunctional therapeutic agent when given as a single agent. Based on the composition, the dose may be delivered once, continuously, e.g., by a continuous pump, or at regular intervals. The dosage may be adjusted locally or systemically as appropriate to achieve the desired drug level. If the subject does not respond adequately to such a dose, a higher dose (or a higher effective dose via a different, more localized delivery route) may be used, to the extent that patient tolerance allows. Continuous IV dosing, e.g., over a 24-hour period, or multiple doses per day, is also contemplated to achieve adequate systemic levels of the compound. By way of example, the dosing regimen can be modified such that the bifunctional therapeutic is administered once, twice, three times, or more per week for any number of weeks, or the bifunctional therapeutic is administered multiple times (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, or 24 times), with administration occurring once per week, once every two weeks, once per three weeks, once per four weeks, once per five weeks, once per six weeks, once per seven weeks, once per eight weeks, once per nine weeks, or once per ten weeks. For example, the bifunctional therapeutic can be administered at least two, three, or four times at the dosage levels cited above, with administration occurring once every four to eight weeks. If the subject does not experience an adverse reaction to the bifunctional therapeutic and / or if one or more symptoms of the cancer improve or remain the same, one or more additional doses can be given, hi some embodiments, the amount of bifunctional therapeutic can be increased as the time between doses increases.

[0156] The biodistribution and pharmacokinetics of bifunctional therapeutic agents may differ for different targeting moieties.For example, large bifunctional therapeutic agents composed of full-length intact antibodies have long plasma and systemic half-lives and tend to remain in circulation.Such bifunctional therapeutic agents are also likely to be excreted through the liver and are less likely to penetrate normal tissues.Conversely, small bifunctional therapeutic agents composed of, for example, targeting peptides or small molecule ligands tend to have short half-lives, be excreted through the kidney / urinary tract, and rapidly penetrate normal tissues and tumors.

[0157] In carrying out the methods of the present disclosure, an administration step is carried out to treat cancer in a subject. In one embodiment, a subject with cancer is selected prior to administration. Such administration may be systemic, or may be via direct or local administration to the tumor site. By way of example, suitable systemic administration methods include, but are not limited to, oral, topical, transdermal, parenteral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, or intranasal, intracavity, or intravesical instillation, intraocular, intraarterial, intralesional, or mucosal application. Suitable local administration methods include, but are not limited to, catheter placement, implantation, direct injection, dermal / transdermal application, or portal vein administration to relevant tissues, or any other local administration technique, method, or procedure commonly known in the art. Methods for affecting the delivery of bifunctional therapeutic agents vary depending on the type of bifunctional therapeutic agent (e.g., having an antibody targeting component or a peptide targeting component) and the disease to be treated.

[0158] The bifunctional therapeutic agents of the present disclosure may be administered orally, for example, with an inert diluent or with an assimilable edible carrier, enclosed in hard or soft shell capsules, compressed into tablets, or taken directly with food. The bifunctional therapeutic agents of the present disclosure may also be incorporated into devices such as time-release capsules or nanotubes for sustained-release administration. Such devices provide flexibility in terms of time and dosage. For oral therapeutic administration, the agents of the present disclosure may be incorporated with excipients and used in the form of tablets, capsules, elixirs, suspensions, syrups, and the like. Such compositions and formulations should contain at least 0.1% of the agent, although lower concentrations may be effective and, in practice, optimal. The percentage of agent in these compositions may, of course, vary and may conveniently be from about 2% to about 60% of the weight of the unit. The amount of the bifunctional therapeutic agent of the present disclosure in such therapeutically useful compositions is such that a suitable dosage will be obtained.

[0159] When the bifunctional therapeutic substance of the present disclosure is administered parenterally, a solution or suspension of the drug can be prepared by dissolving it in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared by dissolving it in glycerol, liquid polyethylene glycol, and mixtures thereof in oil. Exemplary oils are oils of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solutions, and glycols, such as propylene glycol or polyethylene glycol, are preferred liquid carriers, particularly for injectable solutions. Under normal conditions of storage and use, these preparations contain preservatives to prevent the growth of microorganisms.

[0160] Pharmaceutical preparations suitable for injectable use include sterile aqueous solutions or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the dosage form must be sterile and must be fluid to the extent that easy syringability exists. The dosage form must also be stable under the conditions of manufacture and storage, and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

[0161] When systemic delivery of the bifunctional therapeutic agents of the present disclosure is desired, they may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or multidose containers, with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing, and / or dispersing agents.

[0162] Intraperitoneal or intrathecal administration of the bifunctional therapeutics of the present disclosure can also be accomplished using an infusion pump device, which allows for continuous infusion of the desired compound without multiple injections and manipulations.

[0163] In addition to the formulations described above, the bifunctional therapeutic agents may be formulated as depot preparations. Such long-acting formulations may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0164] Another aspect of the present disclosure relates to a pharmaceutical composition comprising a bifunctional therapeutic agent of the present disclosure and a pharmaceutically acceptable carrier.

[0165] Bifunctional therapeutic agents are described above.

[0166] Pharmaceutical compositions containing bifunctional therapeutic agents for use in the methods of the present disclosure may include a pharmaceutically acceptable carrier, one or more active agents, and a suitable delivery vehicle, including, but not limited to, viruses, bacteria, biodegradable microspheres, microparticles, nanoparticles, liposomes, collagen minipellets, and cochleates.

[0167] In one embodiment of the present disclosure, the pharmaceutical composition or formulation is encapsulated in a lipid formulation to form nucleic acid-lipid particles as described in Semple et al., "Rational Design of Cationic Lipids for siRNA Delivery," Nature Biotech. 28:172-176 (2010), WO2011 / 034798 to Bumcrot et al., WO2009 / 111658 to Bumcrot et al., and WO2010 / 105209 to Bumcrot et al., all of which are incorporated by reference herein in their entireties.

[0168] In another aspect of the present disclosure, the delivery vehicle is a nanoparticle. A variety of nanoparticle delivery vehicles are known in the art and are suitable for delivering the bifunctional therapeutic agents of the present disclosure (see, e.g., van Vlerken et al., "Multi-functional Polymeric Nanoparticles for Tumor-Targeted Drug Delivery," Expert Opin. Drug Deliv. 3(2):205-216 (2006), which is incorporated by reference in its entirety).Suitable nanoparticles include poly(β-amino ester) (Sawicki et al., "Nanoparticle Delivery of Suicide DNA for Epithelial Ovarian Cancer Cell Therapy," Adv. Exp. Med. Biol. 622:209-219 (2008), which is incorporated by reference in its entirety), polyethyleneimine-alt-poly(ethylene glycol) copolymer (Park et al., "Degradable Polyethylenimine-alt-Poly(ethylene glycol) Copolymers As Novel Gene Carriers," J. Control Release 105(3):367-80 (2005), which is incorporated by reference in its entirety, and Park et al., "Intratumoral Administration of Anti-KITENIN shRNA-Loaded PEI-alt-PEG Nanoparticles Suppressed Colon Carcinoma Established Subcutaneously in Mice," J. Nanosci. Nanotechnology 10(5):3280-3 (2010)), and liposome-encapsulated siRNA nanoparticles (Kenny et al., "Novel Multifunctional Nanoparticle Mediates siRNA Tumor Delivery, Visualization and Therapeutic Tumor Reduction In Vivo," J. Control Release 149(2): 111-116 (2011), which is incorporated by reference in its entirety. Other nanoparticle delivery vehicles suitable for use in the present disclosure include the microcapsule nanotube devices disclosed in U.S. Patent Application Publication No. 2010 / 0215724 to Prakash et al., which is incorporated by reference in its entirety.

[0169] In another embodiment of the present disclosure, the pharmaceutical composition is contained in a liposome delivery vehicle. The term "liposome" refers to a vesicle composed of amphiphilic lipids arranged in the form of one or more spherical bilayers. Liposomes are unilamellar or multilamellar vesicles with a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes have the advantage of being able to fuse with cell walls. Non-cationic liposomes cannot fuse efficiently with cell walls, but are taken up by macrophages in vivo.

[0170] Some advantages of liposomes include their biocompatibility and biodegradability, their ability to entrap a wide variety of water-soluble and lipid-soluble drugs, and their protection of encapsulated drugs from metabolism and degradation. Important considerations in the preparation of liposomal formulations are the lipid surface charge, vesicle size, and the aqueous volume of the liposomes.

[0171] Liposomes are useful for transporting and delivering active ingredients to the site of action. Because liposome membranes are structurally similar to biological membranes, when liposomes are applied to tissues, they begin to integrate with cell membranes, and as the integration of liposomes and cells progresses, the contents of liposomes are poured into cells where the active agent can act.

[0172] Methods for preparing liposomes for use in the present disclosure include those disclosed in Bangham et al., "Diffusion of Univalent Ions Across the Lamellae of Swollen Phospholipids," J. Mol. Biol. 13:238-52 (1965); U.S. Patent No. 5,653,996 to Hsu; U.S. Patent No. 5,643,599 to Lee et al.; U.S. Patent No. 5,885,613 to Holland et al.; U.S. Patent No. 5,631,237 to Dzau & Kaneda, and U.S. Patent No. 5,059,421 to Loughrey et al., which are incorporated by reference in their entireties.

[0173] In another aspect of the present disclosure, the delivery vehicle is a viral vector. Viral vectors are particularly suitable for delivering nucleic acid molecules, but can also be used to deliver molecules encoding bifunctional therapeutic agents. Suitable gene therapy vectors include, but are not limited to, adenoviral vectors, adeno-associated viral vectors, retroviral vectors, lentiviral vectors, and herpes viral vectors.

[0174] Adenovirus viral vector delivery vehicles can be readily prepared and utilized as described in Berkner, "Development of Adenovirus Vectors for the Expression of Heterologous Genes," Biotechniques 6:616-627 (1988); Rosenfeld et al., "Adenovirus-Mediated Transfer of a Recombinant Alpha 1-Antitrypsin Gene to the Lung Epithelium In Vivo," Science 252:431-434 (1991); WO 93 / 07283 to Curiel et al.; WO 93 / 06223 to Perricaudet et al.; and WO 93 / 07282 to Curiel et al., which are incorporated by reference in their entireties.See Shi et al., "Therapeutic Expression of an Anti-Death Receptor-5 Single-Chain Fixed Variable Region Prevents Tumor Growth in Mice," Cancer Res. 66:11946-53 (2006); Fukuchi et al., "Anti-Aβ Single-Chain Antibody Delivery via Adeno-Associated Virus for Treatment of Alzheimer's Disease," Neurobiol. Dis. 23:502-511 (2006); Chatterjee et al., "Dual-Target Inhibition of HIV-1 In Vitro by Means of an Adeno-Associated Virus Antisense Vector," Science 258:1485-1488 (1992); Ponnazhagan et al., "Suppression of Human Alpha-Globin Gene Expression Mediated by the Recombinant Adeno-Associated Virus 2-Based Antisense Vector," which are incorporated by reference in their entireties. Adeno-associated virus delivery vehicles can be constructed and used to deliver the bifunctional therapeutic agents of the present disclosure to cells, as described in "Adeno-associated Virus 2-Mediated Transduction and Erythroid Cell-Specific Expression of a Human Beta-Globin Gene," J. Exp. Med. 179:733-738 (1994); and Zhou et al., "Adeno-associated Virus 2-Mediated Transduction and Erythroid Cell-Specific Expression of a Human Beta-Globin Gene," Gene Ther. 3:223-229 (1996).The in vivo use of these vehicles is described in Flotte et al., "Stable in Vivo Expression of the Cystic Fibrosis Transmembrane Conductance Regulator With an Adeno-Associated Virus Vector," Proc. Nat'l. Acad. Sci. 90:10613-10617 (1993), and Kaplitt et al., "Long-Term Gene Expression and Phenotypic Correction Using Adeno-Associated Virus Vectors in the Mammalian Brain," Nature Genet. 8:148-153 (1994), which are incorporated by reference in their entireties. Additional types of adenoviral vectors are described in U.S. Pat. No. 6,057,155 to Wickham et al.; U.S. Pat. No. 6,033,908 to Bout et al.; U.S. Pat. No. 6,001,557 to Wilson et al.; U.S. Pat. No. 5,994,132 to Chamberlain et al.; U.S. Pat. No. 5,981,225 to Kochanek et al.; U.S. Pat. No. 5,885,808 to Spooner et al.; and U.S. Pat. No. 5,871,727 to Curiel, which are incorporated by reference in their entireties.

[0175] Retroviral vectors that are modified to form infectious transformation systems can also be used to deliver nucleic acid molecules to target cells.One of these types of retroviral vectors is disclosed in U.S. Patent No. 5,849,586 to Kriegler et al., which is incorporated herein by reference.Other nucleic acid delivery vehicles suitable for use in the present disclosure include the nucleic acid delivery vehicle disclosed in U.S. Patent Application Publication No. 20070219118 to Lu et al., which is incorporated herein by reference in its entirety.

[0176] Regardless of the type of infectious transformation system used, the infectious transformation system must be targeted to deliver the nucleic acid to the desired cell type. For example, to deliver to a cluster of cells (e.g., cancer cells), a high-titer infectious transformation system can be injected directly into the site of the cells to increase the likelihood of cell infection. The infected cells then express a nucleic acid molecule targeting a tumor-associated antigen. This expression system may further contain a promoter to control or regulate the strength and specificity of expression of the nucleic acid molecule in the target tissue or target cell.

[0177] As noted above, the effective dose of the disclosed compositions for treating metastatic disease will vary depending on many factors, including the type and stage of cancer, the means of administration, the target site, the patient's physiological condition, other drugs or therapies administered, and the patient's physical condition related to other medical complications. Treatment dosages may need to be adjusted to optimize safety and efficacy.

[0178] Pharmaceutical compositions of the present disclosure may contain a "therapeutically effective amount" or a "prophylactically effective amount" of a bifunctional therapeutic of the present disclosure. A "therapeutically effective amount" refers to an amount effective to achieve a desired therapeutic result, at dosages and for periods of time necessary to achieve the desired therapeutic result. A therapeutically effective amount of a bifunctional therapeutic may vary depending on factors such as the individual's disease state, age, sex, and weight, and the ability of the bifunctional therapeutic to elicit a desired response in the individual. A therapeutically effective amount is also an amount in which the therapeutically beneficial effects outweigh any toxic or adverse effects of the bifunctional therapeutic. A "therapeutically effective dose" preferably inhibits a measurable parameter, e.g., tumor growth rate, by at least about 20%, more preferably at least about 40%, even more preferably at least about 60%, and even more preferably at least about 80% compared to untreated controls. The ability of a compound to inhibit a measurable parameter, e.g., cancer, can be assessed in animal model systems predictive of efficacy in human tumors. Alternatively, this property of a composition can be evaluated by examining the inhibitory ability of the compound, eg, in vitro inhibition, by assays known to those skilled in the art.

[0179] A "prophylactically effective amount" refers to an amount effective to achieve the desired prophylactic result, at dosages and for periods of time necessary to achieve that result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

[0180] In certain embodiments, the administering step further comprises administering the nucleotide sugar uridine diphosphate galactose (UDP-gal), uridine diphosphate-N-acetylgalactosamine (UDP-NAcGal), and / or guanosine diphosphate-fucose (GDP-fucose).

[0181] UDP-gal, UDP-NAcGal, and / or GDP-fucose can be administered by any suitable route, including, but not limited to, intravenous, subcutaneous, intramuscular, intraperitoneal, oral, rectal, or any other route known in the art. Furthermore, UDP-gal, UDP-NAcGal, and / or GDP-fucose can be administered simultaneously with the targeted bifunctional enzyme or after the bifunctional targeted enzyme. In the latter case, the interval between the targeted enzyme and the nucleotide sugar can be from 1 minute to 1 week. In a preferred embodiment, the interval is from 1 minute to 48 hours.

[0182] The bifunctional therapeutic agents described herein may be used in combination with other therapies. As used herein, "administered in combination" means that two (or more) different treatments are delivered to a subject while the subject is suffering from a disorder. For example, two or more treatments are delivered after a subject is diagnosed with a disorder and before the disorder is cured or eliminated, or before treatment is discontinued for other reasons. In some embodiments, delivery of one treatment is still ongoing when delivery of a second treatment begins, thereby resulting in an overlap in the administration period. This is referred to herein as "simultaneous" or "concurrent delivery." In other embodiments, delivery of one treatment ends before delivery of the other treatment begins. In some embodiments, the combined administration results in a greater effect of the treatments. For example, the effect of the second treatment is greater. For example, the second treatment has a lesser but equivalent effect. Or, the second treatment alleviates symptoms to a greater extent than would be observed if administered in the absence of the first treatment. Or, a similar condition to that of the first treatment is observed. In some embodiments, the delivery is such that the alleviation of symptoms or other parameters associated with the disorder is greater than that observed with one treatment delivered in the absence of the other. The effect of the two treatments may be partially additive, wholly additive, or greater than additive. The delivery may be such that the effect of the first treatment delivered is still detectable when the second treatment is delivered.

[0183] Exemplary therapeutic agents include taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, maytansinoids such as maytansinol (see U.S. Pat. No. 5,208,020, which is incorporated by reference herein in its entirety), CC-1065 (see U.S. Pat. Nos. 5,475,092, 5,585,499, 5,846,545, which are incorporated by reference herein in their entirety), and analogs or homologs thereof. Therapeutic agents include antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechloretharnine, thioepa chlorambucil), and the like. chlorambucil), CC-1065, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamineplatinum(II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and antimitotic agents (e.g., vincristine, vinblastine, taxol, and maytansinoids).

[0184] In other embodiments, the bifunctional therapeutic agent is administered in combination with other therapeutic treatment modalities, including surgery, radiation, cryosurgery, and / or hyperthermia. Such combination therapies may advantageously utilize lower dosages of the administered therapeutic agent, thus avoiding possible toxicities or complications associated with various monotherapies.

[0185] In other embodiments, the bifunctional therapeutic is administered in combination with an immunomodulatory agent, such as IL-1, IL-24, IL-6, or IL-12, or interferon alpha or gamma.

[0186] A further aspect of the present disclosure provides nucleic acid (e.g., polynucleotide) molecules encoding the bifunctional therapeutic agents of the present disclosure. The polynucleotides can be, for example, single-stranded and / or double-stranded DNA, cDNA, PNA, RNA, or a combination thereof, or natural or synthetic polynucleotides, such as polynucleotides with phosphorothioate backbones, and may or may not contain introns, so long as they encode the bifunctional therapeutic agent. Of course, polynucleotides can only encode peptides in which natural amino acid residues are joined by natural peptide bonds. A still further aspect of the present disclosure provides recombinant expression vectors capable of expressing the bifunctional therapeutic agents of the present disclosure. Various methods have been developed for linking polynucleotides, particularly DNA, to vectors, for example, via complementary cohesive ends. For example, complementary homopolymer regions can be added to the DNA segment to be inserted into the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymer tails to form a recombinant DNA molecule.

[0187] Synthetic linkers containing one or more restriction sites provide an alternative method for linking DNA segments to vectors. Synthetic linkers containing various restriction endonuclease sites are commercially available from a number of sources, including International Biotechnologies Inc. New Haven, CN, USA. A desirable method for modifying DNA encoding the bifunctional therapeutic substance of the present disclosure uses the polymerase chain reaction, as disclosed in Higuchi et al., "A General Method of In Vitro Preparation and Specific Mutagenesis of DNA Fragments: Study of Protein and DNA Interactions," Nucleic Acids Res. 16(15):7351-67 (1988), the entire contents of which are incorporated herein by reference. This method can be used, for example, to introduce DNA into a suitable vector by manipulation at an appropriate restriction site, or to modify DNA in other useful ways as known in the art.

[0188] Nucleic acids of the present disclosure may be selected to have codons that are preferred or dispreferred for a particular expression system. By way of example, the nucleic acids may have at least one codon, preferably at least 10% or 20%, changed so that the sequence is optimized for expression in E. coli, yeast, human, insect, NSO, or CHO cells.

[0189] Typically, the polynucleotide encoding the bifunctional therapeutic agent is placed under the control of a promoter that functions in the desired host cell. A wide variety of promoters are known and can be used in the expression vector of the present disclosure, depending on the specific disclosure. The promoter selected usually depends on the cell in which the promoter is active. Optionally, other expression control sequences, such as ribosome binding sites, transcription termination sites, etc., are also included. A construct containing one or more of these control sequences is called an "expression vector." Thus, the present disclosure provides an expression vector into which a nucleic acid molecule encoding a bifunctional therapeutic agent is incorporated for high-level expression in the desired host cell.

[0190] Expression control sequences suitable for use in a particular host cell are often obtained by cloning genes expressed in that cell. Commonly used prokaryotic control sequences are defined herein to include a promoter and optionally an operator for transcription initiation, together with a ribosome binding site sequence, and include the β-lactamase (penicillinase) and lactose (lac) promoter systems (Change et al., Nature 198:1056 (1977), incorporated herein by reference in its entirety), the tryptophan (trp) promoter system (Goeddel et al., Nucleic Acids Res. 8:4057 (1980), incorporated herein by reference in its entirety), the tac promoter (DeBoer, et al., Proc. Natl. Acad. Sci. USA 80:21-25 (1983), incorporated herein by reference in its entirety), and the λ-derived P L Examples of promoters that can be used include commonly used promoters such as the ribosome binding site promoter and N-gene promoter (Shimatake et al., Nature 292:128 (1981), which is incorporated by reference in its entirety). However, any available promoter that functions in prokaryotes can be used.

[0191] To express a bifunctional therapeutic in prokaryotic cells other than E. coli, a promoter that functions in the particular prokaryotic species is required. Such a promoter can be obtained from a gene that has been cloned from that species. Alternatively, a heterologous promoter can be used. For example, the hybrid trp-lac promoter functions in Bacillus in addition to E. coli.

[0192] The expression cassettes of the present disclosure conveniently include a ribosome binding site (RBS). In E. coli, an RBS consists of, for example, a 3-9 nucleotide long nucleotide sequence located 3-11 nucleotides upstream of the start codon (Shine and Dalgarno, "Determinant of Cistron Specificity in Bacterial Ribosomes," Nature 254:34-38 (1975); Steitz, In Biological regulation and development: Gene expression (ed. RF Goldberger), vol. 1, p. 349, 1979, Plenum Publishing, New York, which are incorporated by reference in their entireties).

[0193] For mammalian cells, control sequences include a promoter, preferably an enhancer and polyadenylation sequence derived from immunoglobulin genes, SV40, cytomegalovirus, etc., and may include splice donor and acceptor sequences.

[0194] Either constitutive or regulatable promoters can be used in the present disclosure. Regulatable promoters can be advantageous because they allow host cells to grow to high densities before expression of the bifunctional therapeutic is induced. High levels of heterologous protein expression can slow cell growth in some cases. Inducible promoters are promoters that induce gene expression, where the expression level can be altered by environmental or developmental factors, such as temperature, pH, anaerobic or aerobic conditions, light, transcription factors, and chemicals. Such promoters are referred to herein as "inducible" promoters, and their use allows for control of the timing of bifunctional therapeutic expression. For E. coli and other bacterial host cells, inducible promoters are known to those skilled in the art. These include, for example, the lac promoter, bacteriophage lambda P promoter, and the lac promoter. L promoter, the hybrid trp-lac promoter (Amann et al. Gene 25:167 (1983); de Boer et al. Proc. Nat'l. Acad. Sci. USA 80:21 (1983), which are incorporated by reference in their entireties), and the bacteriophage T7 promoter (Studier et al. J. Mol. Biol (1986); Tabor et al. Proc. Nat'l. Acad. Sci. USA 82: 1074-8 (1985), which are incorporated by reference in their entireties).

[0195] Expression vectors used to express the bifunctional therapeutic agents of the present disclosure often incorporate a selectable marker. These genes can encode gene products, such as proteins, necessary for the survival or growth of transformed host cells grown in selective culture media. Host cells not transformed with a vector containing a selectable gene will not survive in the culture medium. Typical selectable genes encode proteins that confer resistance to antibiotics or other toxins, such as ampicillin, neomycin, kanamycin, chloramphenicol, or tetracycline. Alternatively, a selectable marker may encode a protein that complements an auxotrophic deficiency or supplies a critical nutrient unavailable from complex media. For example, in the case of Bacillus, a gene encoding D-alanine racemase. Often, vectors contain one type of selectable marker that functions, for example, in E. coli or in other cells where the vector is replicated before being introduced into the host cell. Numerous types of selectable markers are known to those skilled in the art.

[0196] The construction of suitable nucleic acid constructs containing one or more of the components listed above uses standard ligation methods, such as those described in the references cited above. The isolated plasmid or DNA fragment is cleaved, adapted, and religated as desired to produce the required nucleic acid construct (e.g., a plasmid). To confirm the correct sequence in the constructed plasmid, the plasmid can be analyzed by standard techniques, such as restriction endonuclease digestion, and / or by sequencing according to known methods. Molecular cloning methods for achieving these purposes are known in the art. A wide variety of cloning methods and in vitro amplification methods suitable for the construction of recombinant nucleic acids are well known to those skilled in the art. Examples of these techniques and instructions sufficient to guide one of skill through many cloning exercises can be found in Berger and Kimmel, Guide to Molecular Cloning Techniques, Methods in Enzymology, Volume 152, Academic Press, Inc., San Diego, Calif. (Berger), and Current Protocols in Molecular Biology, F. M. Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc. (1998 Supplement) (Ausubel), which are incorporated by reference herein in their entireties.

[0197] A variety of common vectors suitable for use as starting materials for constructing the nucleic acid constructs and expression vectors of the present disclosure are well known in the art. For cloning in bacteria, common vectors include pBR322-derived vectors, such as pBLUESCRIP™, and λ-phage-derived vectors. In yeast, vectors include Yeast Integrating plasmids (e.g., YIp5) and Yeast Replicating plasmids (YRp series plasmids) and pGPD-2. Expression in mammalian cells can be achieved using a variety of commonly available plasmids, including pSV2, pBC12BI, and p91023, as well as lytic viral vectors (e.g., vaccinia virus, adenovirus, and baculovirus), episomal viral vectors (e.g., bovine papillomavirus), and retroviral vectors (e.g., murine retrovirus).

[0198] The nucleic acid can then be expressed in a suitable host to produce a polypeptide comprising the bifunctional therapeutic of the present disclosure.Therefore, the nucleic acid encoding the bifunctional therapeutic of the present disclosure is appropriately modified in consideration of the disclosure contained herein and used according to known techniques to construct an expression vector, and then the expression vector is used to transform a suitable host cell for expressing and producing the bifunctional therapeutic of the present disclosure.Such techniques are described below and also include the methods disclosed in, for example, U.S. Patent Nos. 4,440,859, 4,530,901, 4,582,800, 4,677,063, 4,678,751, 4,704,362, 4,710,463, 4,757,006, 4,766,075 and 4,810,648, the entire contents of which are incorporated herein by reference.

[0199] The method for introducing the expression vector into the selected host cell is not particularly critical and is known to those skilled in the art. For example, the expression vector can be introduced into prokaryotic cells, including E. coli, by calcium chloride transformation, and into eukaryotic cells by calcium phosphate treatment or electroporation. Other transformation methods are also suitable.

[0200] The bifunctional therapeutic agents of the present disclosure can also be linked to other bacterial proteins. This approach often results in high yields because normal prokaryotic regulatory sequences direct transcription and translation. lacZ fusions are often used to express heterologous proteins in E. coli. Suitable vectors, such as the pUR, pEX, and pMR100 series, are readily available. In certain applications, it may be desirable to cleave non-enzymatic amino acids from the fusion protein after purification. This can be accomplished with cyanogen bromide, proteases, or factor X. a This can be accomplished by any of several methods known in the art, including cleavage with a factor (see, e.g., Itakura et al., Science (1977) 198: 1056; Goeddel et al., Proc. Natl. Acad. Sci. USA (1979) 76: 106; Nagai et al., Nature (1984) 309: 810; Sung et al., Proc. Natl. Acad. Sci. USA (1986) 83: 561, which are incorporated by reference in their entireties.) A cleavage site can be engineered into the gene for the fusion protein at the desired point of cleavage.

[0201] Multiple bifunctional therapeutic agents can be expressed in a single host cell by placing multiple transcription cassettes in a single expression vector or by utilizing different selectable markers in each expression vector used in the cloning strategy.

[0202] Bifunctional therapeutic agents can be purified according to standard procedures in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis, and the like (see, generally, R. Scopes, Protein Purification, Springer-Verlag, New York (1982); Deutscher, Methods in Enzymology Vol. 182: Guide to Protein Purification., Academic Press, Inc. New York (1990), which are incorporated by reference in their entireties). Substantially pure compositions of at least about 70-90% homogeneity are preferred, with 98-99% or greater homogeneity being most preferred. By way of example, when the targeting moiety of the bifunctional therapeutic agent is an antibody, antibody-binding chromatography, such as ion exchange chromatography, can be used. Ion exchange chromatography can be anion exchange chromatography, cation exchange chromatography, or both. Types of anion exchange chromatography include, but are not limited to, Q Sepharose Fast Flow®, MacroPrep High Q Support®, DEAE Sepharose Fast Flow®, and Macro-Prep DEAE®. Types of cation exchange chromatography include, but are not limited to, SP Sepharose Fast Flow®, Source 30S®, CM Sepharose Fast Flow®, Macro-Prep CM Support®, and Macro-Prep High S Support®.

[0203] To facilitate purification of the bifunctional therapeutics of the present disclosure, the nucleic acid encoding the bifunctional therapeutic may also include a coding sequence for an epitope or "tag" for which an affinity binding reagent is available, i.e., a purification tag. Examples of suitable epitopes include the myc and V-5 reporter genes. Expression vectors useful for recombinant production of fusion proteins bearing these epitopes are commercially available (e.g., the Invitrogen (Carlsbad, Calif.) vectors pcDNA3.1 / Myc-His and pcDNA3.1 / V5-His are suitable for expression in mammalian cells). Additional expression vectors and corresponding detection systems suitable for attaching tags to the bifunctional therapeutics of the present disclosure are known to those of skill in the art, and some are commercially available (e.g., "FLAG" (Kodak, Rochester, NY). Another example of a suitable tag is a polyhistidine sequence that can bind to a metal chelating affinity ligand. Typically, six contiguous histidines are used, although more or fewer than six histidines can be used. A suitable metal chelating affinity ligand that can serve as a binding moiety for a polyhistidine tag includes nitrilotriacetic acid (NTA) (Hochuli, E. (1990) "Purification of recombinant proteins with metal chelating adsorbents" In Genetic Engineering: Principles and Methods, J.K. Setlow, Ed., Plenum Press, New York; commercially available from Qiagen (Santa Clarita, Calif.), which is incorporated by reference in its entirety).

[0204] Purification tags also include maltose-binding domains and starch-binding domains. Purification of maltose-binding domain proteins is known to those skilled in the art. Starch-binding domains are described in WO99 / 15636, the entire contents of which are incorporated herein by reference. [Example]

[0205] The following examples are intended to illustrate the practice of aspects of the present disclosure, but are not intended to limit the scope of the disclosure in any way.

[0206] material and method cell line Human prostate cancer cell lines LNCaP and PC3 were purchased from the American Type Culture Collection (Manassas, VA). CWR22Rv1 was a gift from Thomas Pretlow, MD, Case Western Reserve University. Breast cancer cell line MDA-MB-361 was a gift from Christel Larbouret, Institute of Cancer Research of Montpellier (France). LNCaP, PC3, and CWR22Rv1 were maintained in RPMI 1640 medium supplemented with 2 mM L-glutamine, 1% penicillin-streptomycin, and 10% heat-inactivated fetal bovine serum (FBS) (all supplements were obtained from Gemini Bio-products, West Sacramento, CA). MDA-MB-361 was maintained in L-15 medium (ATCC) supplemented with 1% penicillin-streptomycin and 20% FBS.

[0207] antibody Monoclonal antibody (mAb) J591 anti-FOLH1 / PSMA, mouse and deimmunized, was generated as described in Liu et al., "Monoclonal Antibodies to the Extracellular Domain of Prostate Specific Membrane Antigen Also React With Tumor Vascular Endothelium," Cancer Res. 57:3629-3634 (1997), U.S. Patent No. 7,045,605 to Bander et al., and U.S. Patent No. 7,514,078 to Bander et al., all of which are incorporated by reference herein in their entireties. MAb 3E6 anti-PSMA, horseradish peroxidase-labeled polymer-conjugated goat anti-mouse Ig, and horseradish peroxidase-conjugated rabbit anti-human IgG were purchased from Dako (Carpinteria, CA). MAb 4D5 was purchased as Herceptin (Genentech / Roche). MAb anti-A and anti-B antibodies were purchased from Ortho Diagnostic Systems (Raritan, NJ). For O / H antigen detection, Ulex europaeus lectin, which recognizes α-linked fucose residues, was purchased from Sigma-Aldrich (St. Louis, MO). Donkey anti-human IgG, horseradish peroxidase-conjugated donkey anti-human IgG, alkaline phosphatase-conjugated donkey anti-human IgG, FITC-conjugated donkey anti-mouse Ig, and FITC-conjugated donkey anti-human Ig were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). Anti-Flag M2 was obtained from Sigma-Aldrich. IRDye 800CW-goat anti-mouse secondary antibody was purchased from LI-COR Biosciences (Lincoln, Nebraska).

[0208] DNA plasmids used in this study As outlined in the examples below, a series of plasmids can be constructed for any desired targeting Ab or Ab construct or peptide and any glycosyltransferase, including but not limited to GTB, GTA, and fucosyltransferase (FUT1 or FUT2).

[0209] The DNA plasmids and their protein products that are overexpressed in host cells after transfection or cotransfection are listed below with a brief description. Each plasmid is described by the name of the DNA plasmid (its protein product): a brief description. pMG145 (H chain): Introduction of this plasmid into host cells by transfection produces the huJ591 heavy chain. pMG135 (L chain): Transfection with this plasmid produces the huJ591 light chain (L). pMG145 and pMG135 (huJ591 antibody): Cotransfection of these two plasmids results in the coexpression of the heavy and light chains and functional huJ591 antibody. pMG181 (H chain-GTB): Transfection with this plasmid produces a fusion protein with the huJ591 heavy chain (H) at the N-terminus and GTB at the C-terminus (see below). pMG181 and pMG135 (huJ591-GTB fusion antibody): Cotransfection of these two plasmids produces heavy and light chains containing GTB.

[0210] Construction of GTB and huJ591 or 4D5 heavy chain-GTB (H-GTB) fusion expression plasmids A region of α1,3 galactosyltransferase (GTB) containing the catalytic domain (amino acids 57-354) was subcloned by PCR using the GTB-encoding plasmid pBBBB as a template. Flag and His tags may be added to the 3' end, if desired, to track or aid in purification of the fusion protein. For example, to construct an antibody-GTB fusion protein, the DNA sequence encoding the huJ591 heavy chain (H) was ligated to the GTB catalytic domain DNA sequence, resulting in plasmid pMG181. The same procedure was followed to generate 4D5-GTB or any Ab (or Ab derivative or peptide)-GTB (or the catalytic domain of GTA for A antigens). Alternatively, if it is desired to target the synthesis of the H antigen, the catalytic domain of FUT1 or FUT2 can be incorporated. The glycosyltransferase enzyme is preferentially linked to the C-terminus of either the heavy or light chain of the Ab construct.

[0211] A (G4S)3 spacer sequence was inserted between the Ab sequence and the enzyme sequence. Alternatively, various fusion protein linkers or spacers can be used as described in Chen et al., "Fusion Protein Linkers: Property, Design and Functionality," Adv. Drug Deliv. Rev. 65(10):1357-69 (2013), which is incorporated by reference in its entirety.

[0212] DNA transfection and fusion protein expression To produce huJ591-GTB (also 4D5-GTB) fusion antibodies, CHO cells were co-transfected with pMG181 (H chain-GTB) and pMG135 (L chain) using a FreeStyle MAX (ThermoFisher Scientific) according to the manufacturer's instructions. Five days after transfection, the supernatant containing the fusion antibody was collected and concentrated using an Amicon Ultra 10K centrifugal filter (Merck Millipore).

[0213] Purification of overexpressed fusion proteins huJ591 was purified using protein G-sepharose (GE Healthcare) according to the manufacturer's instructions. J591-GTB was purified using anti-FLAG M2 affinity gel (Sigma-Aldrich) according to the manufacturer's instructions. Briefly, the supernatant containing the fusion protein was incubated with the M2 affinity gel for 2 hours, washed, eluted with 3xFLAG peptide (Sigma-Aldrich), and dialyzed against PBS.

[0214] Western blot analysis The supernatant or purified fraction containing the fusion protein was separated on a 4-20% SDS-PAGE gel (Life Technology) under reducing and non-reducing conditions and transferred to a polyvinylidene fluoride membrane (PVDF) (Millipore, Billerica, MA). The membrane was blocked with 5% dry milk / PBST for 60 minutes. Anti-flag M2 was incubated with the membrane for 60 minutes. After washing, the membrane was incubated with IRDye 800CW-goat anti-mouse secondary antibody for 60 minutes. After washing, the membrane was analyzed using an Odyssey Infrared Imaging System (LI-COR Biosciences).

[0215] immunostaining 24 h before the experiment, cells (2 x 10 5Cells (1 / well) were grown on glass coverslips in 12-well plates. Cells were fixed with 4% paraformaldehyde (PFA) in PBS and then washed three times with PBS. To detect human histo-blood group antigens, mouse monoclonal anti-A or anti-B antibodies were added for 60 minutes at room temperature. After washing with PBS, cells were incubated with FITC-conjugated donkey anti-mouse immunoglobulin for 60 minutes and washed with PBS. HBGA O expression was detected by incubating cells with FITC-conjugated Komatsunagi agglutinin for 60 minutes at room temperature, followed by visualization under a UV microscope. For PSMA detection, huJ591 was added for 60 minutes at room temperature. After washing with PBS, cells were stained with FITC-conjugated anti-human Ig for 60 minutes and washed with PBS. Coverslips were mounted and examined under a UV microscope.

[0216] For immunostaining of tissue sections derived from xenograft tumors, 3E6 was used to detect PSMA expression in paraffin sections, and huJ591 was used for frozen sections. Antibodies against blood group antigens were the same as those described above. Paraffin sections were deparaffinized by placing the slides in Histo-Clear and then rehydrated by washing with graded alcohols and Tris-buffered saline-Tween 20 (TBST). The deparaffinized and rehydrated sections were placed in Target Retrieval Solution pH 9.0 (Dako) and heated in a water bath (95–99°C) for 30 minutes. The sections were washed with TBST. A peroxidase blocker was added for 5 minutes. After washing with TBST, mAb was added for 60 minutes at room temperature. Antibody binding was detected using peroxidase-labeled polymer-conjugated goat anti-mouse Ig and 3,3'-diaminobenzidine (DAB) substrate. Sections were visualized after counterstaining with 10% hematoxylin. Frozen sections were used to detect J591-GTB fusion antibody binding to cell surface PSMA in vivo. Frozen sections were fixed with pre-chilled acetone for 10 minutes and then washed with PBS. Peroxidase block was added for 5 minutes. After washing with PBS, J591-GTB was detected with horseradish peroxidase-conjugated rabbit anti-human IgG followed by counterstaining with DAB as described above. Sections directly incubated with huJ591 were used as a positive control.

[0217] Competitive ELISA Plates were coated overnight at 4°C with 15 μg / ml of 7E11 antibody (an antibody that binds to the N-terminal / cytoplasmic domain of PSMA) dissolved in 0.05 M carbonate buffer (pH 9.5). Wells were blocked with 2% HSA in PBS for 30 minutes at room temperature and washed. A 1:8 diluted LNCaP cell lysate (containing PSMA) was added for 60 minutes at room temperature. After washing with PBS, serial dilutions of mouse J591 antibody (30 μl) were added for 60 minutes, followed by co-incubation with supernatant containing J591-GTB or huJ591 (1.6 μg / ml; 30 μl) overnight at 4°C. After washing, donkey anti-human IgG-alkaline phosphatase (1:1,000) was added for 60 minutes at room temperature. After washing, plates were incubated with pNPP (Sigma) and read at 405 nm.

[0218] In vitro blood group antigen conversion cells (2x10 5 ) were grown on cover slips in 12-well plates for 24 hours. The cover slips were washed with PBS and transferred to a humid chamber. The cells were then incubated with huJ591-GTB (or 4D5-GTB) fusion antibody plus UDP-galactose at 37°C for 30 minutes. After washing with PBS, the cells were fixed with PFA. B antigen conversion on the cell surface was detected by immunostaining as described above.

[0219] Lytic activity of normal human O or A serum after in vitro transformation of cancer cells with HBGA B LNCaP cells were grown in 60-well microtiter plates. Cells were incubated with either native J591 or J591-GTB fusion protein, or neither drug. All wells also contained UDP-gal. Serum from either type A or type O patients was then added as a source of native anti-B Ab and complement. Control wells contained J591 without GTB or without serum. After 3 hours, wells were washed, fixed with methanol, and incubated with 2% Giemsa stain for 25 minutes before washing and reading. Similar methods were used to test a larger panel of suspension prostate and breast cancer cell lines. Lytic activity was assessed by both trypan blue exclusion and propidium iodide uptake measured by FACS.

[0220] In vivo blood group antigen conversion Under a protocol approved by the Institutional Animal Care and Use Committee (IUCUC), 6- to 8-week-old NOD SCID mice (Charles River, Wilmington, MA) were inoculated with 5 x 10 cells suspended in 200 μl Matrigel (Corning Life Sciences, Bedford, MD). 6 Cells were injected subcutaneously. The cell lines LNCaP, CWR22Rv1, PC3, and MDA-MB-361 were used in animal experiments. After 14–21 days, established tumors reached a diameter of 8–10 mm. HuJ591, huJ591-GTB, 4D5, or 4D5-GTB were injected intravenously (IV) or intratumorally. UDP-gal was injected IV, intraperitoneally (IP), or subcutaneously (SQ). Mice were euthanized on days 1, 2, or 3, and tumors and other organs were collected. Half of each tumor was prepared for frozen sectioning using OCT compound. The other half was placed in phosphate-buffered formalin for paraffin section preparation. Immunostaining was performed as previously described.

[0221] An intraperitoneal xenograft model in NOD / SCID mice was also developed using the castration-resistant human PC cell line C4-2-luciferase. In this model, human plasma can be injected IP to provide natural Abs and complement without causing fluid overload when using the IV route. 6 A few days after IP injection of C4-2-luc cells and confirmation of tumor uptake by bioluminescence imaging, two groups of five animals, each with comparable median / range bioluminescence photon flux, received a single IP treatment with J591-GTB, UDP-gal, and human type O serum. For the control group, type O serum was heat-inactivated prior to injection. Total flux was measured for each animal every 3–4 days for approximately two weeks.

[0222] Example 1 - Construction of antibody-glycosyltransferase fusion proteins We first generated chimeric proteins composed of tumor-targeting Abs and glycosyltransferases, prototypic constructs that provide a versatile, modular system with multiple functionalities. (1) Ab specificities are interchangeable to target different tumor-associated antigens. Examples of such tumor antigen targets include, but are not limited to, FOLH1 / PSMA, VEGFr, CD19, CD20, CD25, CD30, CD33, CD38, CD52, CD79, B-cell maturation antigen (BCMA), somatostatin receptors (e.g., SSTR1-5), 5T4, gp100, CEA, mammoglobin A, MelanA / MART-1, PSA, tyrosinase, HER-2 / neu, EGFr, hTERT, MUC1, mesothelin, nectin-4, TROP-2, and many other tumor antigen targets known in the art. The targeting moiety of the structure can vary from intact (full-length dimer) to monomeric single-chain Ab structures, Fab, Fab'2, scFv, or other Ab fragment derivatives, such as minibodies, diabodies, and triabodies. These may retain or lack the FcRn-binding domain. Alternatively, the targeting moiety may be a peptide that binds to the targeted antigen. Examples include, but are not limited to, glutamic acid-urea-lysine derivatives, such as ACUPA (2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid), which binds to FOLH1 / PSMA; somatostatin derivatives that bind to SSTR2; Arg-Gly-Asp (RGD) peptides that bind to α-v / β-3 integrin expressed on proliferating endothelial cells; and other targeting peptides known in the art. These types of targeting agents and their different physical properties allow for tailoring of different pharmacokinetics and biodistribution profiles. For example, large molecular constructs, such as full-length intact Abs containing the FcRn (neonatal receptor) binding site, have long plasma and systemic half-lives and tend to persist in the circulation. Large molecular constructs are more likely to be excreted through the liver rather than the kidney, and are less likely to penetrate normal tissues due to intervening normal cell layers and tight junctions.Conversely, constructs that are small, lack FcRn binding, and are constructed using targeting peptides rather than antibodies tend to have shorter half-lives, are more likely to be excreted through the kidney / urinary tract, and rapidly penetrate normal tissues and tumors. In addition to target binding specificity, these different physical properties, PK, and biodistribution influence the adverse event profile of the resulting drug. (2) The glycosyltransferase component can be modified based on a substantial body of knowledge about natural allelic variants and their respective properties, which can be used to tailor their functionality. The glycosyltransferase component can also include α-gal-transferase, which generates highly immunogenic α-gal epitopes not naturally present in humans. Any enzyme involved in post-translational modification can be used. In addition to glycosylation, other examples include phosphorylation and lipid modification.

[0223] As a further alternative to creating a genetically engineered fusion protein, the targeting agent and the post-translational enzyme can be linked using chemical conjugation of the two separate moieties, and such chemical conjugations are known to those skilled in the art.

[0224] For initial proof-of-concept efforts, we selected three well-characterized and clinically validated Abs: J591 (anti-FOLH1 / PSMA (folate hydrolase-1 / prostate-specific membrane antigen)), 4D5 (trastuzumab; anti-her2), and obexelimab (anti-CD19); four Ab structures: intact dimer, intact monomer, Fab, and scFv; and four glycosyltransferase variants: α1,3 galactosyltransferase (GTB; AF134414), α1-3-N-acetylgalactosaminyltransferase (GTA; AF134415), α-1,3-galactosyltransferase (α-1,3-GalT or α-GalT; EC 2.4.1.87), as well as the following entirely novel structures: GTB transfers a galactose moiety from the nucleotide-donor UDP-gal to the acceptor H antigen via an α1,3 linkage, forming Galα(1-3)[Fucα(1-2)]Galβ1,4 GlcNAc-R (HBGA B). GTB requires that the H antigen be modified with α1,2-linked fucose for activity because transferase B does not add to the unmodified type 2 precursor. α-1,3-GalT transfers a galactose moiety from the nucleotide-donor UDP-gal to Galβ1,4 GlcNAc-R via an α1,3 linkage. This enzyme does not require that the H antigen be modified with α1,2-linked fucose for activity. GTB was chosen because individuals with HBGA types O and A comprise 85-90% of the population (Galili et al., "A Unique Natural Human IgG Antibody With Anti-Alpha-Galactosyl Specificity," J. Exp. Med. 160:1519-1531 (1984), incorporated herein by reference in its entirety). As previously noted, these individuals have high levels of anti-HBGA B antibodies. α-1,3-GalT was chosen because it can add terminal Gal to cells that do not form H antigens, such as cells derived from hematopoietic or mesenchymal cells.The selection of GTB further benefits from its substantially identical structure, resulting in high levels of polyclonal anti-Gal activity (responsible for hyperacute xenograft rejection) that cross-reacts with HBGA B (Macher et al., "The Gal Alpha1,3Gal beta1,4GlcNAc-R (Alpha-Gal) Epitope: a Carbohydrate of Unique Evolution and Clinical Relevance," Biochim. Biophys. 1780:75-88 (2008)), which is incorporated by reference in its entirety. A short cytoplasmic region, transmembrane region, and stem region unnecessary for enzymatic activity were excised from the GTB (or GTA, α-GalT, or FUT) sequence and replaced with the respective antibody (or derivative) or peptide sequence to create a chimeric protein. The antibody or peptide domain binds to the cognate antigen located in the plasma membrane, thereby reconstituting membrane binding. ELISA assays of the chimeric proteins confirmed that the respective Ab binding specificities and immunoreactivities remained intact, regardless of whether intact or fragmented antibodies were used (Figures 2A-2B). 14C-gal incorporation from UDP-14C-gal into a synthetic substrate (fucosyl-lactose (FL)) was also measured as described in Yamamoto et al., "Amino Acid Residue at Codon 268 Determines Both Activity and Nucleotide-Sugar Donor Substrate Specificity of Human Histo-Blood Group A and B Transferases. In Vitro Mutagenesis Study," J. Biol. Chem. 271:10515-10520 (1996), which is incorporated herein by reference in its entirety (Figures 2A-2B). This confirmed the maintenance of high GTB activity.

[0225] In addition to creating such fusion proteins by genetic engineering, one of skill in the art is able to chemically link targeting proteins, peptides, or other biologics to effector enzymes (e.g., glycosyltransferases) that are capable of post-translationally modifying cellular proteins.

[0226] Example 2 - Modulation of the functionality of glycosyltransferase activity Deep knowledge of A, B and O alleles provides ample opportunity to further refine the functionality of this component.For example, among the alternative allelic variants that can be selected, there is the so-called "cisA,B" sequence, which exchanges the two most important amino acid residues (aa266 and 268 (leu and gly) of GTA and aa266 and 268 (meth and ala) of GTB) to create a hybrid sequence (meth and gly) (Yazer et al., "The Cis-AB Blood Group Phenotype: Fundamental Lessons in Glycobiology", Transfus. Med. Rev. 20:207-217 (2006)), which is incorporated herein by reference in its entirety.This cisA,B enzyme sequence synthesizes both HBGA A and B specificity.

[0227] Other sequences are known that allow for the modulation of enzyme activity and thus the efficacy of the enzyme. For example, a completely novel version of GTB was developed based on two naturally occurring mutant alleles of GTA (designated Ae101 and A201). Ae101 has a single-base insertion, and A201 has a single-base deletion. Each results in a frameshift. The frameshift produces transferases with a 37-amino acid extension and a 21-amino acid extension at the C-terminus, respectively. The resulting extended transferases have 30-50 times less enzymatic activity (Yip, "Sequence Variation at the Human ABO Locus," Annals of Human Genetics 66:1-27 (2002)), which is incorporated herein by reference in its entirety). While these two mutant alleles were defined in the context of GTA, no such mutant alleles have been described in the context of GTB. Nevertheless, entirely novel sequences were created by incorporating C-terminal sequence extensions directly into GTB by inserting various amino acid sequences of varying lengths before the stop codon. When four versions of GTB incorporating extensions of 2, 7, 14, and 54 amino acids were tested, GTB activity progressively decreased by up to 93% (Figure 3). This provides a mechanism for adjusting the desired activity level and on / off switch, as described above, by incorporating a cleavable sequence that cleaves the extension in the presence of tumor- or tissue-associated endoproteases or endopeptidases, e.g., PSA, metalloproteinases, etc. The choice of any sequence for the extension is at the discretion of the practitioner, with the only requirements being that the sequence be selected to achieve the desired level of enzymatic activity, which can be measured as described below, and that it be non-immunogenic. Non-immunogenicity may be achieved using sequence information from naturally occurring, non-immunogenic proteins (e.g., albumin) or by methods known in the art for eliciting or determining immunogenicity, for example, by eliminating T-cell binding motifs.

[0228] Example 3 - Inducible expression of HBGA B alloantigen in vitro To demonstrate the functionality of the constructs, the human prostate cancer cell lines LNCaP (PSMA-high), CWR22Rv1 (PSMA-low), and PC-3 (PSMA-negative), all of which are naturally HBGA O, were incubated with chimeric J591 (anti-FOLH1 / PSMA)-GTB or J591 (no GTB) and both UDP-gal in vitro and on xenograft tissue sections derived from SCID mice. Cell lines and tissue sections incubated with chimeric J591-GTB + UDP-gal converted to HBGA B, whereas cell lines and tissue sections incubated with J591 (no GTB) + UDP-gal did not. This demonstrates that GTB was required for conversion (Figure 4).

[0229] In vitro, J591-GTB converted LNCaP (PSMA-high) cells from HBGA O to HBGA B, whereas it did not convert PC3 (PSMA-neg) cells (Figure 5). The high specificity of HBGA conversion was confirmed by testing PC3 cells transfected with PSMA (PC3-PSMA). In these PSMA heterologous expressing cells, only PSMA-positive cells were converted; adjacent PSMA-neg cells were not converted (Figure 6).

[0230] HBGA O LNCaP cells were also co-incubated with type O whole blood plus UDP-Gal and either J591, J591-GTB, or J591-GTB-54 amino acid extension. As shown in Figure 7, J591 did not convert any cells, whereas J591-GTB, with or without extension, converted LNCaP cells from type O to HBGA B but did not convert RBCs.

[0231] Example 4 - Lytic activity of normal human O or A serum after cancer cells were transformed into HBGA B Using an in vitro assay, we tested the lytic ability of normal human O and A serum to lyse prostate or breast cancer cells after they had been converted to express HBGA B. Figures 8A-8D show that LNCaP cells (HBGA O) were lysed when incubated with J591-GTB + UDP-gal + human A (or O) serum (as a source of anti-B and complement components). Removing the human A or O serum and / or replacing J591-GTB with J591 lacking GTB prevented lysis.

[0232] An even larger panel of prostate cancer cell lines, all HBGA O, was assayed by trypan blue exclusion (Figure 9) and propidium iodide uptake by FACS analysis (Figure 10). Four of these lines (LNCaP, VCaP, MDA-PCa-2b, and CWR22Rv1) expressed levels of PSMA ranging from high to low, and all were lysed when incubated with J591-GTB, natural anti-B Ab, and human O or A serum containing endogenous complement. A fifth cell line, PC3, was PSMA-negative, untransduced, and did not lyse (Figures 11A-11B). Similar results were obtained with the breast cancer cell line MDA-MB-361 after transduction with the chimeric mAb 4D5-GTB.

[0233] Example 5 - Conversion of HBGA expression in vivo Since the rapid rejection and destruction of HBGA-mismatched solid organ transplants in humans is a well-documented and well-established phenomenon dating back to the early days of renal allotransplantation (T. Starzl, Experience In Renal Transplantation. (WB Saunders Company, Philadelphia, PA, chapter 6 (1964); L. Altman, Doctors Discuss Transplant Mistake. New York Times. (2003)), which are incorporated by reference in their entireties), significant in vivo experiments have demonstrated the potential for "molecular transplantation" of allogeneic glycosyltransferases, which normally function within the Golgi / ER, into the plasma membrane of tumor cells using systemic, tumor-targeted approaches. The objective of this study was to demonstrate that HBGAs from established human cancers could be converted into highly immunogenic HBGAs by "transplanting" them. For proof-of-concept, we selected two clinically well-established tumor-associated antigens (FOLH1 / PSMA and HER2) from prostate and breast cancers, two of the most common types of solid tumors. Multiple tumor lines expressing a wide range in terms of target expression levels were tested: PSMA-positive prostate cancers LNCaP, C4-2, and CWR22Rv1, and HER2-positive breast cancer, MDA-MB361, compared with NOD. SCID mice were established at subcutaneous sites. J591-GTB or 4D5 / trastuzumab-GTB was administered IV. UDP-gal was administered IV, IP, or subcutaneously. J591-GTB and 4D5 / trastuzumab-GTB transformed PSMA-positive prostate cancer and her2-positive breast cancer, respectively (Figures 10A-10H; see also Figures 12A-12E).

[0234] HBGA B conversion was poor after IP administration of UDP-gal compared with IV or SQ administration. HBGA expression was clearly present at the plasma membrane. As expected, replacement of Ab-GTB with the respective Ab alone did not result in HBGA B expression. No conversion was detectable in any other tissues, and the animals did not develop any evidence of toxicity.

[0235] Example 6 - Antitumor activity in vivo Testing the antitumor activity resulting from the Ab-GTB-induced HBGA expression conversion in animal models posed several challenges because both mice and rats express the cisA,B allele as well as the α1,3GalT allele. As a result, these rodent models are HBGA A-, B-, and α1,3Gal-positive and therefore tolerant to all of these sugar structures. Furthermore, mice have a very weak or inactive complement system (Bergman et al., Cancer Immunol. Immunother. (2000) 49:259-266; Drake et al., "Passive Administration of Antiserum and Complement in Producing Anti-EL4 Cytotoxic Activity in the Serum of C57BL / 6 Mice," J Natl. Cancer Inst. 50:909-14 (1973); Ong et al., "Mouse Strains With Typical Mammalian Levels of Complement Activity," J. Immunol. Methods 125:147-158 (1989)), which are incorporated by reference in their entireties), and in some cases even inhibit the function of complement activity in other species, including humans (Ratelade et al., "Inhibitor(s) of the Classical Complement Pathway in Mouse Serum Limit the Utility of Mice as Infected with Antiserum," which are incorporated by reference in their entireties). "Experimental Models of Neuromyelitis Optica," Mol. Immunol. 62:104-113 (2014)). Indeed, the complement activity of normal human plasma was assayed in the presence of C57BL / 6 plasma. Human complement lytic activity was found to be reduced by approximately 33%.To overcome the lack of natural Abs and the weak or even inhibitory complement system in these animal models, a near-total exchange of the animal's plasma with human type O or type A plasma would be necessary to provide the necessary natural Abs and functional complement proteins. This plasma exchange would be physically infeasible, would result in fluid overload, would not provide the appropriate immunoglobulin biodistribution equilibrium reflective of human steady state, and would be compromised by the inhibitory effects of native mouse plasma. These issues were overcome by developing an intraperitoneal xenograft model in NOD / SCID mice using the castration-resistant human PC cell line C4-2-luciferase. In this model, human plasma could be injected IP to provide natural Abs and complement without causing fluid overload. 6 Several days after IP injection of C4-2-luc cells and confirmation of tumor uptake by bioluminescence imaging, two groups of five animals, each with comparable median / range bioluminescence photon flux, received a single IP treatment with J591-GTB, UDP-gal, and human type O serum. For the control group, type O serum was heat-inactivated prior to injection. Total flux was measured for each animal every 3–4 days for approximately 2 weeks. Animals receiving heat-inactivated serum experienced significant tumor progression by day 13. In contrast, animals treated with serum containing active complement experienced 80% regression of flux compared to control groups (p=0.0032; Figures 13A–13B). Consistent results were obtained from two repeated experiments (Figures 14A–14B).

[0236] Consideration of Examples 1 to 6 The immune response to cancer differs significantly from the response to incompatible allografts. As described herein, a strategy is presented to selectively modify tumor cells to express incompatible HBGA expression, a non-self, highly immunogenic phenotype. The rapid and devastating consequences of HBGA-incompatible allografts in humans were highlighted by Starzl in the early days of kidney allotransplantation (T. Starzl, Experience In Renal Transplantation. (WB Saunders Company, Philadelphia, PA, chapter 6 (1964)), which is incorporated herein by reference in its entirety), leading to HBGA compatibility testing as an essential and critical part of donor-recipient matching. This admonition is repeated and reinforced only when errors occur and the HBGA compatibility requirement is violated, which is a rare occurrence (L. Altman, Doctors Discuss Transplant Mistake. New York Times (2003)), which is incorporated herein by reference in its entirety).

[0237] To implement this strategy, clinically validated, tumor-restricted antibodies (exemplified by anti-FOLH1 / PSMA and anti-HER2) were fused with GTB to generate a single bifunctional protein. Targeted glycosyltransferases (GTs) have been similarly constructed using a variety of antibody fragments, peptides / ligands, and constructs. While the outcomes of incompatible ABO allotransplantation in humans are well documented, the challenge in this effort has been to molecularly "graft" posttranslational glycosyltransferase functions, normally found in the Golgi, onto the tumor (or neovascular endothelial) cell surface, and to do so in a systemically administered, tumor-targeted manner.

[0238] These chimeric proteins successfully converted HBGAs in various cancer cell lines both in vitro and in vivo. No off-target HBGA conversion or toxicity was observed in animal studies. HBGA-incompatible cells, as shown herein, induce complement-mediated lysis, a response that is expected to occur in cancer patients, as has been demonstrated many times in clinical transplant settings (L. Altman, Doctors Discuss Transplant Mistake. New York Times (2003); T. Starzl, Experience In Renal Transplantation. (WB Saunders Company, Philadelphia, PA, chapter 6 (1964)), each of which is incorporated by reference in its entirety).

[0239] The biosynthesis of neo-HBGAs requires the presence of both GT and (fucosylated) H antigen "acceptor structures" on glycoproteins and glycolipids of target cells for the addition of the HBGA (Milland et al., "ABO Blood Group and Related Antigens, Natural Antibodies and Transplantation," Tissue Antigens 68:459-466, incorporated herein by reference in its entirety). (2006). Because a variety of cancers, including those of the lung, stomach, colorectum, breast, prostate, ovary, bladder, and pancreas, express H antigens, these tumor types would be candidates for this strategy. Normal non-target cells do not undergo HBGA conversion because (1) the targeted GTB (or GTA) enzyme does not bind to them, and (2) many normal cell types (e.g., bone marrow, liver, spleen, kidney, myocardium, central and peripheral nervous system, etc.) do not have the required HAg, preventing GTB (or GTA) transferase activity at these sites. FOLH1 / PSMA expression is highly variable. FOLH1 / PSMA-positive neovasculature has been reported in tumor neovasculature of various tumors, but is absent in the vasculature of normal tissues. Examples of tumor types with FOLH1 / PSMA-positive neovasculature include kidney, lung, colon, stomach, breast, brain, pancreas, liver, bladder, esophageal, adrenal, head and neck, melanoma, and brain tumors. Testicular, lymphatic, and sarcomas, although uncommon, can occasionally be FOLH1-positive. Targeting FOLH1 / PSMA expression in tumor neovasculature provides a means to alter HBGA expression within the vascular bed of a wide variety of tumors.This, in turn, would lead to the same hyperacute rejection phenomenon seen in erroneous HBGA solid tissue allografts (L. Altman, Doctors Discuss Transplant Mistake. New York Times (2003); T. Starzl, Experience In Renal Transplantation. (WB Saunders Company, Philadelphia, PA, chapter 6 (1964)), which are incorporated by reference herein in their entireties.

[0240] The enzymatic nature of the reaction results in an amplification effect, because each targeted enzyme molecule converts a large number of acceptor molecules. Furthermore, not only is the tumor-associated antigen targeted by the Ab itself enzymatically converted, but all neighboring molecules within the enzyme's range are also enzymatically converted. Since most cell surface molecules have multiple glycosylation sites, such as FOLH1 / PSMA, which has 10 glycosylation sites (20 if FOLH1 / PSMA is normally expressed as a homodimer), the amount of non-self HBGA sites that can be generated by this approach is quite large. Furthermore, glycoproteins secreted by targeted angiogenic or tumor cells are also HBGA-converted, leading to complement activation in the tumor microenvironment, thereby enhancing the immune environment surrounding the tumor.

[0241] The multiplication of these above factors, i.e., enzymatic amplification, conversion of directly targeted molecules to adjacent molecules and secreted glycoproteins, and abundant glycosylation sites, should result in unprecedented high immunogenic antigen expression levels by tumor cells and within the tumor microenvironment, even for weakly expressed tumor-associated antigen targets. Because HBGA O and A patients comprise approximately 85% of the population, we utilized GTB in our proof-of-concept efforts. Furthermore, because polyclonal anti-gal activity that prevents xenotransplantation cross-reacts with HBGA B (Macher et al., "The Gal alpha1,3Gal beta1,4GlcNAc-R (alpha-Gal) Epitope: a Carbohydrate of Unique Evolution and Clinical Relevance," Biochim. Biophys. 1780:75-88 (2008)), which is incorporated by reference in its entirety), inducible expression of HBGA B by tumors and / or their blood supply renders them targets for unprecedented levels of attack by complement-fixing antibodies that can mediate high levels of inflammation and hyperacute rejection. This strategy may be expanded to cover HBGA O, A, and B patients (approximately 95% of the population) by using a GT with both A and B activity. This is possible with a single nucleotide / amino acid change in GTA, 803G>C (Gly268Ala), a naturally occurring mutation in the so-called cisAB GT, which generates both HBGA A and B. This approach would be applicable to all patients except AB patients (approximately 5% of the population) who have no natural anti-A or anti-B antibodies.

[0242] The methods described herein share many features with, and complement, recent successful immunotherapeutic approaches: Similar to CAR-T and bispecific Ab approaches that utilize the lytic mechanism of T cells, this approach uses the lytic mechanism of the complement cascade. Beyond direct lytic effects, induction of the complement cascade within the tumor microenvironment serves as a bridge to improve the efficacy of cellular immune responses to promote T cell priming (Kopf et al., "Complement Component C3 Promotes T-cell Priming and Lung Migration to Control Acute Influenza Virus Infection," Nature Med. 8:373-378 (2002), incorporated herein by reference in its entirety), and upon C3 activation of APCs (Baudino et al., "C3 Opsonization Regulates Endocytic Handling of Apoptotic Cells Resulting in Enhanced T-cell Responses to Cargo-Derived Antigens," Proc. Natl. Acad. Sci. USA 111:1503-1508 (2014); Surace et al., "Complement is a Central Mediator of Radiotherapy-Induced Tumor-Specific Antigens," incorporated herein by reference in its entirety). Immunity and Clinical Response”, Immunity 42:767-777 (2015)).Furthermore, it has recently been shown that the release of free C3d, a fragment of C3, depletes Tregs (through apoptosis), increases the infiltration of CD8+ T cells that produce perforin, TNF-α, and IFN-γ, and reduces PD-1 expression by T cells (Platt et al., "C3d Regulates Immune Checkpoint Blockade and Enhances Antitumor Immunity," JCI Insight. 2:e90201 (2017), incorporated by reference in its entirety). Furthermore, activation of the complement system generates chemotactic factors such as C3a and C5a, which induce inflammation and recruit inflammatory cells. This would transform a "cold" tumor microenvironment into a "hot" one more supportive of the immune response. In summary, the approach described herein offers the potential to broaden the breadth and intensity of immune attacks against cancer by directly utilizing the humoral immune system and complement cascade, as well as its role in enhancing the cellular immune response.

[0243] Example 7 - B-conversion of MM1-S using anti-CD19-GTB 15-17 show the ability to convert CD19-positive / HBGA O-positive myeloma cells to express HBGA B. In this case, MM1-S myeloma cells passaged in tissue culture were examined by fluorescence-activated cell sorting (FACS) using mouse monoclonal antibodies against CD19, CD20, CD38 (Figure 15), HBGA A, and HBGA B (Fisher Scientific (Ortho)), and Ulex-FITC or Ulex-Dylight (Vector Labs) to detect HBGA O (Figures 16A-16B). MM1-S cells were incubated with each antibody for 1 hour, washed, and then incubated with an appropriate secondary antibody, such as anti-mouse IgM-Alexa 488 or 647 (Jackson ImmunoResearch). In this case, the primary antibody was IgM or tagged anti-mouse IgG when the primary antibody was IgG. After another wash, the cells were analyzed by FACS. As shown in Figure 17, MM1-S cells were incubated with anti-CD19-GTB fusion protein plus UDP-gal, and HBGA B expression was compared to untreated cells by FACS.

[0244] Figure 15 shows that MM1-S myeloma cells are CD20 negative and CD19 + , and CD38 + Figures 16A-16B show that MM1-S cells are HBGA A- and B-negative (Figure 16A), but HBGA O-positive (Figure 16B). Figure 17 shows that MM1-S cells incubated with anti-CD19-GTB fusion protein plus UDP-gal are converted to high-level HBGA B expression compared to untreated cells.

[0245] These experiments demonstrate another example of targeting and transforming tumors that express a foreign antigen: HBGA B. In this case, the target is CD19, a B-cell marker that is also present in B-cell neoplasms. This is a hematopoietic tumor type, whereas prostate (PSMA) and breast (HER2) are examples of solid tumors, as shown in other examples.

[0246] Example 8 - Targeting glycosyltransferases via small molecule ligands as an alternative to antibodies or antibody derivatives Figure 18 demonstrates that targeting of GTA, GTB, or α-gal can be achieved not only with antibody-based constructs but also with peptide / small molecule ligand-based targeting agents. In this case, the GTB enzyme was conjugated with 2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid (ACUPA), a galactose-urea-lysine-based ligand that binds to PSMA. To achieve high levels of conjugation, a PEG1500 spacer was used between the ACUPA and GTB moieties. This provided sufficient steric freedom for ACUPA to bind to the PSMA enzyme pocket without steric hindrance from the GTA / GTB enzyme, which is much larger than ACUPA.

[0247] Figure 18 shows that ACUPA-PEG1500-GTB can convert LNCaP cells from HBGA O to HBGA B (left panel). No conversion occurred when pure GTB without the targeting ACUPA moiety was used (right panel).

[0248] The flexibility of using a variety of targeting moieties, ranging from large 150 kd antibodies to smaller antibody-derived formats such as monomers (75 kd), Fab'2 (100 kd), Fab (50 kd), and scFv (25 kd), as well as short peptides such as ACUPA (1.0 kd), allows for the construction of fusion proteins with different pharmacokinetic and biodistribution properties. Larger fusion proteins tend to circulate longer, remain in the blood compartment for longer periods, and be eliminated via the liver, whereas smaller constructs tend to have shorter serum half-lives, reach / contact tumor targets more quickly, and be eliminated via the kidney. These various options can be utilized to tailor therapy to the requirements of different tumor types (e.g., hematologic tumors vs. solid tumors).

[0249] Example 9 - Specificity and accuracy of conversion; absence of bystander effect As shown in Figures 19 and 20, the breast cancer cell line SK-BR5 (PSMA-negative) was co-cultured with the LNCaP (PSMA-positive) prostate cancer cell line. These cells can be distinguished by their characteristic morphology: SK-BR5 cells are spherical and can be seen in two clusters near the center and top of the field of view in Figure 19 (red circles). LNCaP cells are elongated, and these cells also express GFP as an identifying marker.

[0250] When the cultures were treated with J591-GTB + UDP-gal, HBGA B (stained with Cy5 (purple)) appeared only on the PSMA-positive cells. The adjacent cluster of PSMA-negative SKBR5 cells (highlighted in a red circle) did not convert to HBGA B, even though they were in close proximity to the converted cells. Similarly, Figure 20 shows the same distinct cell types. The left panel shows all of the cell nuclei stained with DAPI. The middle panel shows a spindle-shaped LNCaP cell with green fluorescence due to GFP expression. The right panel, after treatment with J591-GTB + UDP-gal, shows that only the PSMA-positive LNCaP cells expressed HBGA B, whereas the PSMA-negative SKBR5 cells remained HBGA B-negative.

[0251] This demonstrates a high degree of specificity and the absence of bystander effects: even neighboring cells are not transduced unless they are directly targeted and bind to the fusion protein.

[0252] Example 10 - Specificity Index Determination Figures 21A-21B and Figure 22 quantify the specificity index for the same two PSMA-positive and PSMA-negative cell lines. Anti-PSMA-GTB concentrations, ranging from 100 μg / mL to 0.003 μg / mL, were incubated with each cell line individually in the presence of the nucleotide donor UDP-gal. Conversion specificity was quantified by FACS by comparing the J591 (anti-PSMA)-GTB concentration required to convert LNCaP (PSMA+) to HBGA B with SK-BR5 (PSMA-negative) cells. Both cell lines are O+. FACS histograms are shown in Figures 21A-21B. Note that concentrations above 12.5 μg / mL overlap the 12.5 μg / mL curve and have been removed from the FACS histograms for ease of viewing.

[0253] Concentrations of J591-GTB up to 100 μg / mL do not induce B-conversion of SK-BR5. In comparison, concentrations as low as 0.012 μg / mL of anti-PSMA-GTB begin to induce conversion of PSMA-positive cells. This data is displayed in histogram form in Figure 22. This indicates that the fusion protein is at least 8,196-fold more specific for PSMA-positive cells than for PSMA-negative cells. This is due to the ability of the fusion protein to directly bind to PSMA-positive cells, assemble on the cell surface of PSMA-positive cells, and perform its enzymatic function. If the enzyme is not bound to the target cell surface, the enzymatic reaction is significantly weaker or absent. For practical reasons, concentrations above 100 μg / mL were not tested. The calculated specificity index may actually be significantly greater than 8,000-fold.

[0254] Figures 19-22 demonstrate the remarkable specificity of the conversion reaction, restricted to target-positive cells, and the lack of a bystander effect, where cells adjacent to the conversion / target-positive cells are not converted if the cells are target-negative and do not bind the fusion protein.

[0255] Example 11 - Both cell surface and secreted glycoproteins are glycosylated by this method Because both cell surface and secreted glycoproteins are glycosylated by the same cellular process in the Golgi / endoplasmic reticulum, in addition to the HBGA conversion of cell surface molecules, glycoproteins secreted by target cells are also HBGA converted. In this exemplary case, the secreted glycoprotein is converted to HBGA B-positive. LNCaP cells were treated with J591-GTB + UDP-gal for 5 hours (10 μg / ml anti-PSMA-GTB + 100 μM UDP-gal). As a negative control, another set of LNCaP cells was incubated with 10 μg / ml anti-PSMA-GTB without UDP-gal. As a positive control, cell surface conversion was measured alongside unconverted cells, which served as background controls. After 5 hours of incubation, spent media containing secreted glycoproteins was collected from each set of cells and concentrated 10-fold using an Amicon 3,000 dalton cutoff. Spent media was adsorbed onto the wells of the plate and analyzed by ELISA for the presence of HBGA B using IgM anti-HBGA B followed by anti-mouse IgM-alkaline phosphatase.

[0256] FIG. 23 shows that the transformed medium was positive for the presence of HBGA B on secreted proteins compared to the negative control (untransformed spent medium).

[0257] This demonstrates that HBGA B conversion is not limited to the cell surface but also includes glycoproteins secreted by target cells. In vivo, this suggests that these converted secreted glycoproteins penetrate the tumor extracellular space, bind to natural anti-B antibodies, induce complement, generate a proinflammatory microenvironment, recruit inflammatory and immune cells via chemotaxis, and further convert the tumor microenvironment into a "hot" one.

[0258] Example 12 - Analysis of α1,3 Galactosyltransferase (aGalT) Utilization In addition to using human glycosyltransferase A or glycosyltransferase B enzymes, another embodiment utilizes the enzyme α1,3 galactosyltransferase (aGalT, EC 2.4.1.87), which functions in all mammals but is inactive in humans and Old World monkeys due to evolutionary mutations. GTA, GTB, and α1,3GalT are highly homologous and are thought to have originated from the same ancestral gene. Like GTB, αGalT adds terminal α1,3 galactose to the carbohydrate chains of cell-surface and secreted glycoproteins and glycolipids. However, unlike GTB, αGalT can add its Gal in the absence of the H antigen fucose acceptor structure. Because all humans lack functional αGalT and therefore do not express this terminal α1,3Gal epitope, they have high levels of anti-αGal antibodies of the IgM, IgG, IgA, and IgE classes, which are estimated to comprise approximately 1% of all circulating immunoglobulins. It is the immunogenicity of this α1,3Gal epitope that prevents xenotransplantation from other mammals that have functional aGalT and express terminal α1,3Gal on the surface of tissues, including blood vessels.

[0259] The use of αGalT eliminates the need to select GTA or GTB depending on the patient's blood type. This allows for the use of this treatment approach in AB blood type patients who lack natural antibodies to HBGA A or B but have antibodies to α1,3Gal. αGalT does not require the H antigen fucose as an acceptor, broadening the range of tissue types it can address. For example, hematopoietic cells and mesenchymal-derived cells (and tumors derived from these cell types) as well as other tissues do not express the H antigen acceptor. These tissues / tumors cannot be addressed by either GTA or GTB, but may be addressed by α1,3GalT.

[0260] One concern with using αGal transferase is whether the enzyme itself might be immunogenic in humans if humans do not express a functional version of the enzyme. If this were true, the enzyme would need to be humanized or deimmunized for repeated administration. This concern was assessed by assaying sera from 50 randomly selected patients of different blood types to see if anti-αGalT antibodies were present.

[0261] ELISA assays were performed by coating α1,3GalT (500 ng / ml) overnight at 37°C in 96-well Half Area High Bind microplates. Negative control wells were not coated with enzyme. After washing and blocking with PBS-HSA (5%), sera from 50 different donors were added to the plates for 2 h at room temperature (RT). This included sera from 21 type O patients, 20 type A patients, 3 type B patients, and 6 type AB patients. After washing, anti-α1,3GT antibodies were detected by adding an anti-human IgG+IgM-Alk Phos antibody solution, followed by PNPP, and reading the plate at 405 nm. To ensure proper coating of α1,3GT, α1,3GT was tagged with a His tag, so this protein was detected using an anti-His-tag antibody (positive control). As another control, to ensure that the AP anti-human IgG+IgM was functional, 500 ng / ml BSA was coated and anti-BSA antibodies from human serum (HBGA A) were measured using the same method.

[0262] None of the 50 sera were found to contain antibodies to α1,3GalT (Figures 24A-24B). This is presumably due to the homology of a wide variety of glycosyltransferases, including but not limited to GTA and GTB. This result demonstrates that the αGalT enzyme can be used in fusion proteins to generate αGal epitopes without concern for the fusion protein's immunogenicity. Therefore, deimmunization or humanization is unlikely to be required.

[0263] Example 13 - Expression and purification of recombinant α1,3 galactosyltransferase (aGalT) Similar to the GTA and GTB approaches, we constructed an anti-CD19 scFv fused to a portion of the α1,3GalT sequence (aa 90-376). The scFv sequences used were derived from Seattle Genetics' denintuzumab (Den) and Xencor's obexelimab (Obx), which recognize and bind to both cynomolgus monkey CD19 and human CD19. The same (G4S)3 spacer / linker as previously described for the Ab-GTB construction was used. For αGalT, we selected the marmoset sequence, which has 376 amino acid residues and conforms to the general topology of glycosyltransferases: a 6-aa cytoplasmic domain, a 16-aa transmembrane domain, and 354 aa in the luminal domain containing the enzymatic activity.

[0264] The stem region of marmoset α1,3GT consists of 67 amino acids and spans amino acids 23–89 of the luminal portion of the enzyme. This can be removed without affecting enzyme activity. The truncated 90–376 α1,3GT was functional and selected for the fusion protein. A His tag was added to this enzyme. The construct was expressed in Expi293F cells and purified using a metal affinity column.

[0265] SDS-PAGE electrophoresis probed with anti-his revealed a highly pure preparation of the desired construct at the appropriate predicted molecular weight (Figure 25).

[0266] Example 14 - Investigation of functionality and specificity of anti-CD19 scFv-αGalT constructs To demonstrate the functionality and specificity of the anti-CD19 scFv-αGalT construct, we chose a hematopoietic target: CD19 on Raji B lymphoma cells, which express neither the H antigen acceptor structure nor HBGA A or B. CD19 is also a validated tumor target. In addition to functionality, we assessed specificity by comparing αGal addition to CD19+ Raji cells co-incubated with CD19-neg MM1.S cells.

[0267] The CD19-positive cancer cell line Raji-GFP was mixed with CD19-negative cancer cells (MM1.S) at different ratios and incubated with the scfv-αGalT construct (10 μg / ml) and UDP-Gal (5 mM) for 1 hour at 37°C. The presence of the α1,3Gal epitope was then assessed by flow cytometry using an anti-α1,3Gal antibody. Raji-GFP cells were used to distinguish between Raji-GFP and MM1.S cells.

[0268] The fusion protein bound to CD19-positive Raji cells, saturating at 1–10 μg / mL, but not to CD19-negative MM1.S cells (Figures 26A–26B). The anti-CD19 scFv-αGalT construct added terminal α1,3Gal to CD19-pos Raji cells but not to CD10-neg MM1.S cells, even when CD10-neg MM1.S cells were present in 30-fold excess over CD19-pos Raji cells (Figure 27). MM1.S never became αGal-positive in the presence of scfv-αGalT fusion protein plus UDP-Gal, even at high ratios to Raji cells.

[0269] α1,3GalT itself lacks the scFv binding domain and does not add the Gal moiety, demonstrating that binding via the antibody (or fragment) portion of the fusion protein is required for α1,3Gal addition (Figure 28). Furthermore, when UDP-gal was not added, Gal was not added to target cells. In the presence of UDP-gal, the α1,3Gal moiety was added, but it did not generate the HBGA B epitope, as evidenced by the lack of binding of antibodies against HBGA B (Figure 28).

[0270] Example 15 - Ability of anti-CD19 scFv-aGalT to transform fresh human lymphocytes Similarly, we tested the ability of anti-CD19 scFv-aGalT to transduce fresh human lymphocytes. To avoid skewing the results due to the presence of the anti-CD19 construct, we used anti-CD20 to identify B cells in this experiment. Cells were incubated with the indicated concentrations of UDP-gal alone, ObxCD19-αGalT alone, or both ObxCD19-αGalT and UDP-gal. Binding of CD19-αGalT (x-axis) and expression of the αGal epitope (y-axis) were measured using a dual-channel FACS (Figure 29). An untreated negative control was also performed.

[0271] CD20-negative cells did not bind the fusion protein and were not converted to express α1,3Gal (Figure 29, upper panel). CD20-positive cells (Figure 29, lower panel) showed binding of the fusion protein and were converted to express α1,3Gal only when UDP-gal was also added.

[0272] Example 16 - Lytic functionality of human sera from different blood group donors against CD19-positive Raji-GFP cells The lytic functionality of human sera from donors with different blood types against CD19+ Raji-GFP cells was tested. CD19+ Raji-GFP cells were incubated with Obx-αGT (10 μg / ml) with or without UDP-Gal (5 mM) at 37°C for 1 h. Serum from different donors was then added to the cells and incubated at 37°C for 4 h. Cell viability was assessed by measuring GFP expression by flow cytometry.

[0273] When UDP-gal was not provided as a nucleoside donor to complete the anti-CD19 scFv-aGalT conversion and express the terminal α1,3Gal, only background lysis was observed (Figure 30). However, when UDP-gal was included and α-gal was converted, human serum lysed the converted cells. In this experiment, group O and group A sera were found to induce greater lysis than group B or AB sera.

[0274] Example 17 - Conversion and lysis of fresh human B cells with autologous serum We extended the above to examine the conversion and lysis of fresh human B cells using autologous serum (from the same donor). Here, we also measured anti-α1,3Gal IgG and IgM levels in individual donors. Human PBMCs from donors with different blood types were incubated with Obx-αGT (10 μg / ml) and UDP-Gal (5 mM) for 1 hour at 37°C. Cell aliquots were analyzed by FACS for binding of human IgG and human IgM using anti-γ chain-specific or anti-μ chain-specific antibodies. Serum from the same donor was then added to another cell aliquot and incubated for 4 hours at 37°C. B cell depletion was measured by flow cytometry using anti-CD20.

[0275] The greatest degree of lysis of transformed cells was found in type A and type O patients. This coincided with the anti-α1,3 Gal levels of each patient (Figures 31A-31B). This suggests that measuring anti-α-gal before treatment can predict whether a patient is likely to respond to this treatment approach. It also suggests that some patients, particularly type B or AB, may benefit from priming with exposure to α1,3 Gal antigen to stimulate even higher levels of anti-α-gal antibodies. This could occur by subcutaneously administering an α-gal-containing polysaccharide or glycoprotein at least one week before this therapeutic approach. Alternatively, induction of the α-gal epitope during the first treatment cycle may help stimulate anti-α-gal antibody production so that it is present for subsequent cycles. One of the techniques in the art is to evaluate a series of patients for pretreatment anti-α-gal levels and the relationship between pretreatment anti-α-gal levels and response, and determine a threshold value below which a response is unlikely to occur without priming.

[0276] Example 18 - Determination of the optimal concentrations of anti-CD19 scFv-aGalT and UDP-gal to generate human donor CD19 cell lysis using autologous serum We determined the optimal concentrations of anti-CD19 scFv-aGalT and UDP-Gal for generating human donor CD19 cell lysis using autologous serum. Human PBMCs from HBGA type A donors, known to induce serum-mediated lysis of αGal-converted cells, were incubated with various concentrations of Obx-αGT and UDP-Gal at 37°C for 1 hour. Serum from the same donor was then added to the cells and incubated at 37°C for 4 hours. Binding, α1,3Gal transfer, and B cell depletion were assessed by flow cytometry.

[0277] Anti-CD19 scFv-aGalT saturated CD19 cells at approximately 10 μg / mL (Figures 32A-32C). The expression of α1,3-gal was highest at a UDP-gal concentration of approximately 10 mM. B cell lysis was maximized with 10 μg / mL of anti-CD19 scFv-aGalT and UDP-gal concentrations ranging from 5 to 20 mM. B cell lysis progressively decreased at concentrations >10 μg / mL, especially at concentrations >=25 μg / mL, which exceeds the saturation point of CD19. This is likely due to unbound anti-CD19 scFv-aGalT competing for UDP-gal, thereby reducing the UDP-gal available for cell-bound anti-CD19 scFv-aGalT.

[0278] The concentrations of scFv-aGalT and UDP-gal may vary depending on the cancer target antigen, and their density and lytic efficacy on tumor cell membranes may vary depending on the level of anti-α1,3Gal antibodies (IgM and / or IgG and / or IgA and / or IgE). All of these parameters can be measured before treatment, and one skilled in the art can determine the optimal concentrations of the various components for treating each individual patient.

[0279] Example 19 - Engineering of anti-CD19 scFv-αGal transferase Obexelimab-scFv-α-1,3 Gal (SEQ ID NO:63) was constructed by fusing the obexelimab single-chain variable fragment (scFv) to the N-terminus of marmoset-derived α-1,3 galactosyltransferase (aa 90-376) via a (G4S)3 linker in a vH-vL orientation. A 6His tag was added to the C-terminus of the fusion protein to enable affinity chromatography purification.

[0280] The protein was produced at WuXi Biologics. Briefly, the target DNA sequence (SEQ ID NO:63) encoding obexelimab-scFv-α-1,3Gal was codon-optimized, synthesized, and subcloned into an expression vector protected by WuXi Biologics' intellectual property rights. The fusion protein was expressed by transient transfection in CHO cells scaled up to 2L. Obexelimab-scFv-α-1,3Gal was purified from cell culture supernatant using a three-step column purification process. Nickel affinity chromatography in the initial capture step, followed by anion exchange chromatography and then size exclusion chromatography, resulted in 95% protein purity with an endotoxin level of <1 EU / mg. The purified protein was formulated in 20 mg / ml histidine buffer, pH 6.0. Protein purity was assessed by SDS-PAGE and SEC-HPLC, and endotoxin levels were tested.

[0281] Example 20 - In vivo treatment of non-human primates with anti-CD19 scFv-αGal transferase fusion protein + UDP-Gal Next, in vivo treatment of non-human primates with anti-CD19 scFv-αGal transferase fusion protein plus UDP-Gal resulted in increased CD19 + We investigated whether this resulted in a reduction in B cell numbers or toxicity.

[0282] Two cynomolgus monkeys (each weighing 5 kg) underwent baseline blood tests to confirm acceptable test values ​​and to measure baseline B and T cell counts. The cynomolgus monkeys were then intravenously injected with anti-CD19 scFv-αGal transferase (SEQ ID NO:63) at time 0, followed by UDP-gal.

[0283] Complete blood counts, serum chemistries, liver function tests, and total lymphocyte, B cell, and T cell counts were measured at 1, 4, and 24 hours after treatment, and on days 7, 14, 30, and 60 (Figure 33).+ / CD3 - B cell numbers were determined by examining fluorescence, and CD20 was used to avoid misinterpretation of B cell numbers due to the presence of anti-CD19 scFv.

[0284] Treatment of the first subject monkey with anti-CD19 scFv-α-Gal transferase + UDP-Gal resulted in an increase in CD19 / CD20 expression 7 days after treatment. + B cells were reduced by 70%, a reduction that persisted for 8 weeks before returning to baseline levels. More recently, a second monkey given an even higher dose of anti-CD19 scFv-α-Gal transferase showed an 80% reduction in B cells at the first measurement taken at 4 hours. This monkey had no visible signs of toxicity as observed by a veterinarian. The monkey's weight did not change. At the time of blood testing, the monkey had no measurable signs of toxicity. In the first monkey, blood test values, except for CD19 / CD20 counts, remained stable over the 2-month follow-up. The second monkey only had data up to 48 hours but is still being studied.

[0285] These results demonstrate that non-human primates can be safely treated with the methods disclosed herein, and that treatment results in significant reduction of target cells.

[0286] Example 21 - Engineering tumor-targeting bifunctional therapeutic proteins Tumor-targeting fusion proteins were constructed by genetically fusing the heavy chain of a tumor-targeting antibody with a glycosyltransferase enzyme. In the examples described herein, GTA (SEQ ID NO:64) and GTB (SEQ ID NO:65) are derived from known human sequences, while αGalT is derived from a marmoset sequence (SEQ ID NO:66). All post-translational enzymes used in the examples presented herein were naturally expressed in the vesicular membranes of the Golgi and / or endoplasmic reticulum. To construct the bifunctional fusion proteins described herein, portions of the enzymes not required for enzyme function (e.g., extravesicular regions, transmembrane regions, and stem regions) were removed.

[0287] As previously described herein, the tumor-targeting portion of the fusion protein can be a full-length Ab, Fab'2, Fab, scFv, monomeric Ab, or any Ab / immunoglobulin derivative thereof. The enzyme portion of the fusion protein can be any post-translationally modified enzyme. The sequence is generally human, humanized, primatized (from a non-human primate), or otherwise deimmunized. Attachment of the targeting portion to the enzyme can be with or without a linker / spacer. In the examples provided herein, a (G4S)3 (SEQ ID NO:67) linker / spacer is used, but any linker / spacer known to those skilled in the art can be used.

[0288] The preparation of these fusion proteins is modular, such that any tumor / tissue targeting moiety can be fused to any post-translational enzyme, according to the several examples provided herein. The sequences used in the engineering and creation of the huJ591 and 4D5 bifunctional therapeutics are shown in Table 7.

[0289] Table 7: Sequence TIFF2023551305000031.tif67161TIFF2023551305000032.tif250161TIFF2023551305000033.tif250161TIFF2023551305000034.tif140161

[0290] huJ591-GTB huJ591-GTB (H chain) (SEQ ID NO:34) was constructed by linking the huJ591 heavy chain (SEQ ID NO:68) to the N-terminus of human GTB (aa57-354) (SEQ ID NO:69). huJ591-LC (L chain) (SEQ ID NO:36) was constructed by adding a 6His-tag (SEQ ID NO:70) to the C-terminus of huJ591-LC (SEQ ID NO:70) to facilitate affinity chromatography purification.

[0291] The DNA sequences encoding the heavy and light chains were subcloned into the pcDNA3.1 expression vector. Protein production was achieved using a transient expression method by cotransfection of the heavy and light chains into CHO cells. The huJ591-GTB fusion protein was purified from cell culture supernatants by nickel affinity chromatography and evaluated by SDS-PAGE.

[0292] huJ591Fab-GTB huJ591Fab-GTB (H chain) (SEQ ID NO:37) was constructed by linking a truncated fragment of the huJ591 heavy chain (VH-CH1-partial hinge sequence) (SEQ ID NO:72) to the N-terminus of human GTB (aa57-354) (SEQ ID NO:69). A Myc / his tag (SEQ ID NO:73) was added to the C-terminus to facilitate expression monitoring and affinity chromatography purification. huJ591-LC (L chain) (SEQ ID NO:39) encodes the huJ591 light chain sequence (SEQ ID NO:71).

[0293] The DNA sequences encoding the heavy and light chains were subcloned into the pcDNA3.1 expression vector. Protein production was achieved using a transient expression method by cotransfection of the heavy and light chains into CHO cells. The Fab-GTB fusion protein was purified from the cell culture supernatant by nickel affinity chromatography and evaluated by SDS-PAGE.

[0294] huJ591-HC67-GTB huJ591-HC67-GTB (heavy chain) (SEQ ID NO:40) was constructed by linking the huJ591 heavy chain (SEQ ID NO:74) to the N-terminus of human GTB (aa 57-354) (SEQ ID NO:69) via a (G4S)3 (SEQ ID NO:67) linker. The changed aa are indicated in bold, double-underlined type in Table 4 and in bold type in Table 7. J591-LC (light chain) (SEQ ID NO:42) was constructed by adding a 6His-tag (SEQ ID NO:70) to the C-terminus of J591-LC (SEQ ID NO:71) to facilitate affinity chromatography purification.

[0295] The monomeric Fc fusion protein was produced as follows: DNA sequences encoding J591HC67-GTB and the L chain were synthesized, subcloned into an expression vector, and cotransfected into CHO cells. The cell culture supernatant was collected. The J591HC67-GTB fusion protein was purified using nickel affinity chromatography and evaluated by SDS-PAGE.

[0296] huJ591-HC67-GTB54aa huJ591-HC67-GTB54aa (H chain) (SEQ ID NO:43) was modified from huJ591-HC67-GTB (H chain) (SEQ ID NO:74) by adding a 54aa tail (SEQ ID NO:75) to the C-terminus of the GTB. huJ591-LC (L chain) (SEQ ID NO:45) was constructed by adding a 6His-tag (SEQ ID NO:70) to the C-terminus to facilitate affinity chromatography purification.

[0297] Protein production was achieved by cotransfection of the heavy and light chains into CHO cells using a transient expression method. The huJ591-GTB fusion protein was purified from cell culture supernatants by nickel affinity chromatography and evaluated by SDS-PAGE.

[0298] huJ591scFv-Fc67-GTB huJ591scFv-Fc67-GTB (SEQ ID NO:46) encodes (N- to C-terminally) the huJ591 single-chain variable fragment (scFv) / J591Fc fragment (SEQ ID NO:76), human GTB (aa 57-354) (SEQ ID NO:69). A (G4S)3 (SEQ ID NO:67) linker was inserted between the Fc (SEQ ID NO:76) and GTB (SEQ ID NO:69).

[0299] The DNA sequence encoding huJ591scFv-Fc67-GTB (SEQ ID NO:46) was synthesized, subcloned into an expression vector, and transfected into CHO cells. The cell culture supernatant was collected. The huJ591scFv-Fc67-GTB (SEQ ID NO:46) fusion protein was purified using nickel affinity chromatography and evaluated by SDS-PAGE.

[0300] huJ591scFv-GTB huJ591scFv-GTB (SEQ ID NO:48) encodes (from the N-terminus to the C-terminus) a deimmunized version of the huJ591 single-chain variable fragment (scFv) (SEQ ID NO:77), human GTB (aa 57-354) (SEQ ID NO:69). A (G4S)3 (SEQ ID NO:67) linker was added between the scFv (SEQ ID NO:77) and GTB (SEQ ID NO:69). A Myc / his tag (SEQ ID NO:73) was added to the C-terminus to facilitate expression monitoring and affinity chromatography purification.

[0301] The DNA sequence encoding huJ591scFv-GTB (SEQ ID NO:48) was subcloned into the pcDNA3.1 expression vector. Protein production was achieved by transfecting the plasmid into CHO cells using a transient expression method. The huJ591scFv-GTB fusion protein was purified from cell culture supernatants by nickel affinity chromatography and evaluated by SDS-PAGE.

[0302] GTA Constructions The following recombinant proteins were also generated using the human GTA (aa 57-354) sequence (SEQ ID NO:78) in place of the GTB sequence (SEQ ID NO:69) in the above DNA construct: huJ591-GTA (SEQ ID NO:35), huJ591Fab-GTA (SEQ ID NO:38), huJ591-HC67-GTA (SEQ ID NO:41), huJ591scFv-Fc67-GTA (SEQ ID NO:47), and huJ591scFv-GTA (SEQ ID NO:49).

[0303] Trastuzumab (4D5) construct To target HER2 on the surface of breast and other cancers, the trastuzumab (4D5) sequence was substituted for the huJ591 sequence in the DNA constructs described herein to generate the following recombinant proteins: 4D5-GTA (SEQ ID NO: 51), 4D5Fab-GTA (SEQ ID NO: 54), 4D5HC67-GTA (SEQ ID NO: 57), 4D5scFv-Fc67-GTA (SEQ ID NO: 60), 4D5scFv-GTA (SEQ ID NO: 62), 4D5-GTB (SEQ ID NO: 50), 4D5Fab-GTB (SEQ ID NO: 53), 4D5HC67-GTB (SEQ ID NO: 56), 4D5scFv-Fc67-GTB (SEQ ID NO: 59), and 4D5scFv-GTB (SEQ ID NO: 61).

[0304] While preferred embodiments have been depicted and described in detail herein, it will be apparent to those skilled in the relevant art that various modifications, additions, substitutions, etc., can be made without departing from the spirit of the disclosure and are therefore deemed to be within the scope of the disclosure as defined in the following claims.

Claims

1. a targeting moiety that targets a tumor-associated antigen; an enzyme that, when delivered to the tumor by the targeting moiety, enzymatically converts the tumor phenotype to an incompatible allograft or xenograft phenotype, said enzyme being linked to said targeting moiety; 13. A bifunctional therapeutic for treating cancer comprising:

2. 2. The bifunctional therapeutic agent of claim 1, wherein the tumor-associated antigen is selected from the group consisting of FOLH1 / PSMA, VEGFR, CD19, CD20, CD25, CD30, CD33, CD38, CD52, B-cell maturation antigen (BCMA), CD79, somatostatin receptor, 5T4, gp100, CEA, MelanA / MART-1, MAGE, NY-ESO-1, PSA, tyrosinase, HER-2, HER-3, EGFR, hTERT, MUC1, mesothelin, nectin-4, TROP-2, tissue factor, and CA-125.

3. 3. The bifunctional therapeutic of claim 1 or 2, wherein the targeting moiety is selected from the group consisting of an antibody or antigen-binding fragment thereof, a protein, a peptide, an aptamer, and a small molecule ligand.

4. 4. The bifunctional therapeutic of claim 3, wherein the targeting moiety is an antibody or an antigen-binding derivative or fragment thereof.

5. 5. The bifunctional therapeutic of any one of claims 1 to 4, wherein the targeting moiety and enzyme are genetically engineered to produce a fusion protein or the targeting moiety and enzyme are chemically linked.

6. 2. The bifunctional therapeutic of claim 1, wherein the targeting moiety is ACUPA [2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid] chemically linked to an enzyme with an intervening PEG spacer.

7. The bifunctional therapeutic agent of any one of claims 1 to 6, wherein the enzyme is an enzyme involved in post-translational modification and is selected from the group consisting of transferases, glycosyltransferases, and active portions thereof.

8. 8. The bifunctional therapeutic of claim 7, wherein the glycosyltransferase is selected from the group consisting of α-gal-transferase, glycosyltransferase A (Gly268Ala), glycosyltransferase A (α1-3-N-acetylgalactosaminyltransferase), glycosyltransferase B (α1-3-galactosyltransferase), fucosyltransferase, and active portions thereof.

9. 9. The bifunctional therapeutic of any one of claims 1 to 8, wherein the enzyme comprises a second amino acid sequence appended to its C-terminus, optionally the second amino acid sequence comprises a cleavable amino acid sequence between the enzyme and the appended second sequence, and optionally the cleavable amino acid sequence is cleavable by PSA, matrix metalloproteinase, or cathepsin B.

10. The bifunctional therapeutic agent of any one of claims 1 to 9, wherein the tumor having a tumor-associated antigen expresses the H antigen.

11. 11. The bifunctional therapeutic agent of any one of claims 1 to 10, wherein the tumor having the tumor-associated antigen is derived from a cancer selected from the group consisting of colorectal cancer, prostate cancer, lung cancer, gastric cancer, breast cancer, blood cancer, cervical cancer, endometrial cancer, ovarian cancer, bladder cancer, kidney cancer, brain cancer, liver cancer, esophageal cancer, adrenal cancer, head and neck cancer, melanoma, and pancreatic cancer.

12. 12. The bifunctional therapeutic of claim 11, wherein the cancer is prostate cancer.

13. 13. The bifunctional therapeutic of claim 12, wherein the targeting moiety targets the prostate-specific membrane antigen (PSMA) / folate hydrolase 1 (FOLH1) receptor.

14. 14. The bifunctional therapeutic of claim 11 or 13, wherein the targeting moiety is a PSMA receptor antibody or a derivative of a PSMA receptor antibody.

15. 15. The bifunctional therapeutic of claim 14, wherein the targeting moiety is an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:28 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:29, or selected from the group consisting of J415, J533, and E99.

16. 12. The bifunctional therapeutic of claim 11, wherein the cancer is breast cancer.

17. 17. The bifunctional therapeutic of claim 16, wherein the targeting moiety targets a HER receptor family member.

18. 18. The bifunctional therapeutic of claim 16 or 17, wherein the targeting moiety is an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:30 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:

31.

19. 12. The bifunctional therapeutic of claim 11, wherein the cancer is a hematological cancer of the B-cell lineage.

20. 20. The bifunctional therapeutic of claim 19, wherein the targeting moiety targets CD19.

21. 21. The bifunctional therapeutic of claim 19 or 20, wherein the targeting moiety is the monoclonal antibody obexelimab or denintuzumab.

22. a targeting component that targets the prostate-specific membrane antigen (PSMA) / folate hydrolase 1 (FOLH1) receptor; a glycosyltransferase or an active portion thereof that, when delivered to a tumor by said targeting moiety, enzymatically converts a tumor phenotype to an incompatible allograft or xenograft phenotype, said glycosyltransferase or an active portion thereof being linked to said targeting moiety; 13. A bifunctional therapeutic for treating cancer comprising:

23. The targeting moiety is A complementarity determining region 1 (CDR-H1) comprising an amino acid sequence of SEQ ID NO:10 or a modified amino acid sequence of SEQ ID NO:10, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:10; a complementarity determining region 2 (CDR-H2) comprising an amino acid sequence of SEQ ID NO:13 or a modified amino acid sequence of SEQ ID NO:13, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:13; A complementarity determining region 3 (CDR-H3) comprising an amino acid sequence of SEQ ID NO:16 or a modified amino acid sequence of SEQ ID NO:16, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:16; and a heavy chain variable region comprising a complementarity determining region 1 (CDR-L1) having an amino acid sequence of SEQ ID NO:19 or a modified amino acid sequence of SEQ ID NO:19, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:19; a complementarity determining region 2 (CDR-L2) having an amino acid sequence of SEQ ID NO:22 or a modified amino acid sequence of SEQ ID NO:22, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:22; A complementarity determining region 3 (CDR-L3) having an amino acid sequence of SEQ ID NO:25 or a modified amino acid sequence of SEQ ID NO:25, wherein the modified sequence has at least 80% sequence identity to SEQ ID NO:25; A light chain variable region comprising Including, 23. The bifunctional therapeutic substance of claim 22.

24. 24. The bifunctional therapeutic of claim 23, wherein the targeting moiety comprises a heavy chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

28.

25. 25. The bifunctional therapeutic of claim 23 or 24, wherein the targeting moiety comprises a light chain variable region comprising an amino acid sequence at least 80% identical to SEQ ID NO:

29.

26. 23. The bifunctional therapeutic of claim 22, wherein the targeting moiety comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:28 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:

29.

27. 27. The bifunctional therapeutic of any one of claims 22-26, wherein the glycosyltransferase or active portion thereof is selected from the group consisting of α-gal-transferase, glycosyltransferase A (Gly268Ala), glycosyltransferase A (α1-3-N-acetylgalactosaminyltransferase), glycosyltransferase B (α1-3-galactosyltransferase), fucosyltransferase, and active portions thereof.

28. A bifunctional therapeutic substance according to any one of claims 1 to 27, and Pharmaceutically acceptable carriers 23. A pharmaceutical composition comprising:

29. A nucleic acid molecule encoding a bifunctional therapeutic substance according to any one of claims 1 to 27.

30. A nucleic acid construct comprising the nucleic acid molecule of claim 29.

31. A recombinant expression vector comprising the nucleic acid molecule of claim 29.

32. A recombinant host cell transformed with the nucleic acid molecule of claim 29, the nucleic acid construct of claim 30, or the recombinant expression vector of claim 31.

33. A pharmaceutical composition comprising a bifunctional therapeutic agent according to any one of claims 1 to 27 for use in a method for treating cancer, said method comprising administering the bifunctional therapeutic agent to a subject having cancer under conditions effective to treat cancer.

34. The pharmaceutical composition of claim 33, wherein the subject is a human.

35. The pharmaceutical composition of claim 33 or 34, wherein the method further comprises administering uridine diphosphate galactose (UDP-gal), uridine diphosphate-N-acetylgalactosamine (UDP-NAcGal), and / or guanosine diphosphate-fucose (GDP-fucose).

36. The pharmaceutical composition of any one of claims 33 to 35, wherein the cancer is selected from the group consisting of colorectal cancer, prostate cancer, lung cancer, gastric cancer, breast cancer, blood cancer, cervical cancer, endometrial cancer, ovarian cancer, bladder cancer, kidney cancer, brain cancer, liver cancer, esophageal cancer, adrenal cancer, head and neck cancer, melanoma, and pancreatic cancer.